NEXT SCIENCE®

NEXT SCIENCE®

2021 // ANNUAL REPORT

NEXT SCIENCE LIMITED ACN 622 382 549

#NextScienceHeals

TABLE OF CONTENTS

NEXT SCIENCE®



See the innovative
Next Science team in action

OUR PURPOSE

NEXT SCIENCE®

Our primary purpose at Next Science is to heal patients and save lives by addressing the impacts of biofilms on human health, and to commercialise our XBIO technology platform for shareholders. We have a unique opportunity to change the trajectory of the war on infection by providing solutions that eliminate biofilms, and their incumbent bacteria, fungi and viruses.

#NextScienceHeals

PATIENT CASE STUDY

SURGX® Sterile Antimicrobial Gel

XPERIENCE™ No Rinse Antimicrobial Solution

CASE STUDY

Podiatry

SURGX®: A Practical Application in a Post-Operative Setting

Approximately 4.5 million dog bites occur each year in the U.S., accounting for 1% of injury-related emergency department (ED) visits and $53.9 million in estimated inpatient costs (Holmquist, 2008). Nearly 1 in 5 of these wounds becomes infected (CDC, 2015). When patients wait more than 24 hours to visit the ED, they often have clinically evident infection and inflammation (Kramer, 2010), which typically include a polymicrobial mixture of animal oral flora (Thomas, 2011). The biofilm forming bacteria in the oral cavity of dogs can be inoculated into the bite wound and plays a major factor in delayed wound healing (Zambori, 2013). SURGX® has proven uniquely effective for mitigating the risks of these types of surgical infections.

The patient, a frail 61-year-old female tripped over her elderly dog and was bitten on her left foot at the site of a previous bunion surgery. She attempted self-care at home, exceeding the 24-hour window to obtain early anti-biofilm intervention. By day four, the bacteria had developed into an infection, when she went to the ED for urgent care.

By this time, the patient was in pain, her foot red, swollen, and filled with fluid. The ED team performed an incision and drained the wound infection, because of her age and poor health state, admitting the patient to hospital for management and IV antibiotics. The initial treatment failed to resolve the infection, the patient was transferred to the surgery team for further intervention to clean and drain the wound. Two additional bedside incision and drainage attempts were performed.

However, by day seven her condition had worsened , requiring a more thorough wound debridement and irrigation under anesthesia. Post-operative treatment included 14 days of Augmentin and topical EO2 oxygen therapy, tissue grafting (Epi-Fix). She was discharged to home. However, by the end of the month during outpatient follow-up, her wound had begun to degrade despite multiple types of therapies, including surgical debridement, IV and oral antibiotics, topical oxygen, and wound grafting. This cycle, where a wound appears to respond, then leads to a worsening infection, is a cardinal sign of a biofilm infection.

In mid-Sept. – more than one month after the dog bite – Dr. Anthony Iorio, DPM, MPH, Director of Surgical Department applied SURGX® to the patient's wound and continued each week during her follow-up wound visits, noting clinical improvement each week until by October 22, the wound was completely closed.

Developed for incision management, Dr. Iorio's use of SURGX® in the post-operative environment demonstrates the value of SURGX® as a compelling resource in surgical infection management.

TREATMENT TIMELINE

25 July 20
- Patient sustains dog bite

29 July 20
- Patient went to the ED for urgent care
- Initial wound incision and drainage attempt
- Patient admitted to the hospital for management and IV antibiotics

30 July 20
- Infection unresolved
- Patient transferred to surgery team for surgical intervention

31 July 20
- Second and third wound incision and drainage attempts
- Infection unresolved

1 August 20
- Surgical wound debridement and irrigation under anesthesia

10 August 20
- Patient discharged 10 days after surgical debridement
- Clinical improvements with only redness remaining at the incision site

26 August 20
- Outpatient follow-up visits revealed degradation of the wound, a clinical photo of a biofilm infection

17 September 20
- Weekly applications of SURGX® begin in mid-Sept.

22 October 20
- Wound healed and completely closed

#NextScienceHeals

PHYSICIAN TESTIMONIALS

"I use SURGX® on my polytrauma patients and have seen a tremendous difference in the outcome of both surgical and open wounds. Several of the patients I see also have co-morbidities such as diabetes and hypertension, that can delay healing and increase the risk for infection. With the use of SURGX® I've been able to prevent biofilms and bioburdens on incisions and deep wound."

Dr. Robert M Harris, MD
Orthopedic traumatologist

SURGX Sterile Antimicrobial Gel

"Chronic ulcerations can have serious negative consequences to patients. Patients with diabetic foot ulcers have 47% mortality rate and if they have the comorbid condition of peripheral vascular disease, mortality rises up to 64%. BLASTX® is an amazing product that has no known antimicrobial resistance, it attacks biofilm and prevents it from reforming. Importantly, it destroys biofilm without harming healthy human tissue. I have applied BLASTX® to over 20,000 patients with no adverse effects. As a physician it is important to me to have the best tools in my toolkit so that I can treat these problems, because when we save their limbs, we save their lives."

Dr. Matthew Regulski
Podiatric Surgery Specialist

BLASTX DISCOVER THE X FACTOR

"Patients come to see me and have an expectation that I can help improve their situation, whether that be a hip replacement or a knee replacement. There is an expectation that I can help improve their quality of life. I take this responsibility very seriously and look to do everything within my powers to provide this outcome. All surgical procedures come with an element of risk, and as a surgeon I do everything I can to minimize this risk. My biggest concern with any procedure is infection, my second biggest concern is infection, and my third biggest concern is infection. While there are often a number of risk factors outside of a physician's control, such as co-morbidities, BMI, smoking etc, we typically control all other factors to ensure a successful outcome. XPERIENCE™ is a product that I routinely use during my surgical procedures to help reduce the risk of infection. I know that with XPERIENCE™ my patients receive ongoing protection against bacteria over an extended period of time compared to other irrigation solutions. My personal view is that the irrigation landscape has evolved and I that with the new technologies available, physicians need to irrigate with purpose."

Dr. Ravi Bashyal
Orthopaedic Surgeon

XPERIENCE™ No Rinse Antimicrobial Solution

#NextScienceHeals

XPERIENCE™
No Rinse Antimicrobial Solution

In April 2021, XPERIENCE™ No Rinse Antimicrobial Solution received FDA clearance to be sold as a medical device in the United States. This non-toxic technology does not need to be rinsed from the surgical site after closure, offering up to five hours of protection in helping to prevent surgical site and post-operative infections.

XPERIENCE™ is designed for use in virtually every open orthopedic surgical case, with an initial focus on shoulder, hip, knee, trauma and podiatry.

XPERIENCE™ is being championed by leading orthopaedic surgeons, four of whom hosted a panel discussion at the American Academy of Orthopaedic Surgeons (AAOS) annual conference in September 2021.

LEARN MORE AT: nextscience.com/xperience

Watch a presentation from
Dr. Ravi Bashyal,Orthopaedic Surgeon,
at AAOS

XPERIENCE™
LAUNCH

IMMEDIATE IMPACT
(APRIL TO FEBRUARY 2021):

USED BY 196 SURGEONS

IN 100 HOSPITALS*

This novel irrigant demonstrates high efficacy against both planktonic bacteria and bacterial biofilms

Ravi K. Bashyal, MD
Orthopaedic Surgeon,
NorthShore University HealthSystem,
Chicago, IL

* As of 17 Feb. 2022

NEW PARTNERSHIPS

In 2021, Next Science announced two additional partnerships: Tela Bio, Inc. and Triad Life Sciences, Inc.

#NextScienceHeals

TELA BIO® SURGICAL RECONSTRUCTION COMPANY
SCIENCE. VALUE. INNOVATION.

The distribution agreement grants TELA Bio, Inc. exclusive rights across the US plastic reconstructive surgery market for the sale and marketing of a white labelled version of XPERIENCE™ (Site Guard Surgical Solution). The agreement also grants TELA Bio, Inc. a first right of negotiation for the EU market, upon successful CE approval for XPERIENCE™. The agreement includes an annual licensing fee plus transfer price arrangements and minimum purchase amounts to retain exclusivity.

The agreement term is 10 years and automatically extends for an additional period of 10 years unless notice is given by either party that they do not wish to extend.

In the US alone, over 5 million plastic reconstructive procedures are done each year. TELA Bio, Inc.'s immediate point of focus will be the breast augmentation and reconstruction market of over 400,000 procedures per year.

TRIAD LIFE SCIENCES™
Engineered by Nature, *Powered* by Science

The agreement grants Triad Life Sciences, Inc. exclusive rights for the sale and marketing of a white labelled version of TORRENTX™ (TridentX™ Wound Wash) across the US wound care market, excluding use in a sterile operating environment. The agreement term is 5 years and includes minimum purchase amounts to retain exclusivity.

Dear Fellow Shareholders,

I am pleased to present Next Science's Annual Report for the financial year ended 31 December 2021.

It was an honour for me to be elected by the Board as Chair of Next Science Limited in May 2021. Next Science has a unique opportunity to make a real difference to the lives of people across the globe with its unique patented products proven to be effective in preventing and treating biofilm-based bacteria. Our people (including the Board) are committed to our purpose, to heal people and save lives, and they are dedicated in pursuing our objective of making our products available worldwide.

2021 was a record sales year for us with sales contributions across all Next Science in-market products. We made good progress in executing our strategy to accelerate market adoption of our products despite disruptions resulting from the Covid-19 pandemic including significant reductions in the number of surgical procedures conducted in our principal market of the United States.

The securing of FDA approval for XPERIENCE™ our advanced no rinse surgical irrigation solution, in April 2021, was an important milestone for Next Science. The Board continues to believe that XPERIENCE™ offers Next Science the greatest product opportunity to date with the potential to accelerate the Company's revenue growth.

Optimising our distribution partnerships as well as our manufacturing relationships was a significant focus during 2021 and in early 2022. The company was able to convert a legal complaint from our longstanding distribution partner, Zimmer Inc. over commercialisation and distribution rights to XPERIENCE™, into an improved and enhanced relationship encompassing a new US distribution arrangement for XPERIENCE™ as well as a refreshed Bactisure™ distribution arrangement.

The new US distribution arrangement for XPERIENCE™ means Zimmer's 2,600 specialist joint reconstruction sales team will be selling XPERIENCE™.

In the second half of 2021, we established a new exclusive distribution relationship with TELA Bio, Inc., a NASDAQ listed company focused on commercial stage medical technologies in the soft tissue reconstruction market, for the sale of XPERIENCE™ in the US plastic surgery market.

Combined with our contracted commissioned sales force primarily focused on the orthopaedic market, we are well placed to generate an uplift in the representation of Next Science's products to the US market.

To support anticipated sales growth, we supplemented our manufacturing capacity and diversified our supply chains by broadening our relationship with Holopak in Germany to include XPERIENCE™. We also focused on developing all our manufacturing relationships to ensure they continue to meet our business requirements as we grow.

We successfully transitioned BLASTX® distribution back to Next Science in April 2021 creating opportunities for us to sell to a wider customer set. Customer responses have been positive, enabling us to expand the BLASTX® customer base under the direct sales model.

6. CHAIR MESSAGE

As we move through 2022, we are expanding our BLASTX® coverage into acute care using our direct sales network.

Throughout 2021, and continuing into 2022, Next Science has prioritised minimising the impacts of COVID19 on the business and safeguarding the health and welfare of our staff.

With the US healthcare sector playing such an important role for our business and our main office being located in Jacksonville, Florida we were delighted that travel restrictions eased during 2021 allowing our CEO and Managing Director, Judith Mitchell, to temporarily relocate to the US and be present on the ground in leading our US team. The Board is greatly appreciative to Judy for making this commitment.

With the emerging recovery in the US surgery market, there is much to be excited about for Next Science in 2022. We expect to benefit from our significantly expanded sales coverage in the US for XPERIENCE™ and SURGX® as well as the launch of TORRENTX™ in the US under the TridentX Wound Wash brand and the launches of XPERIENCE™ and BLASTX® in Australia and New Zealand.

We have recently strengthened our balance sheet, having successfully completed a placement of new shares to institutional and sophisticated investors supplemented by a share purchase plan, to enable all eligible shareholders to participate at the same offer price. These funds ensure we have the working capital to support our growth plans.

We are also looking forward to further strengthening our US leadership structure in 2022 with the anticipated recruitment of a President, US to lead the US business.

In 2022, the company will be focused on continuing to expand doctor and patient access to our suite of patented products and accelerate broader market adoption, as we pursue our purpose of healing people and saving lives.

On behalf of the Board, I wish to thank all our employees for their continued loyalty and dedication during a challenging year. I also wish to thank our shareholders, many of whom have been with us since our listing on the ASX, for their continued encouragement, excitement and support.

In addition to expressing thanks to our people, I would like to add my thanks to my colleague Directors on the Board for their dedicated commitment to Next Science, its shareholders and our purpose of healing people and saving lives.

Professor Mark Compton AM
Chair

NEXT SCIENCE®
A Different Approach, Superior Results

In 2021, Next Science achieved record sales with revenues increasing by 160% on the prior year. This result was driven primarily by growth in Bactisure ™ sales and a combination of surgical market recovery, the return to Next Science of distribution responsibility for BLASTX®, and the new product launch of XPERIENCE™ which was approved by the FDA for sale in the US in late April.

We also made further progress in building market awareness for our prevention and treatment products for the health care market. The benefits of our product range are compelling. Our products deliver better patient outcomes, without driving up antimicrobial resistance (ie. their use does not contribute to the development of medicine resistant 'superbugs') and allow physicians to treat more patients and reduce complications such as surgical site infection. As a result, we reduce the overall cost of healthcare.

To support sales of BLASTX® and launch XPERIENCE™, we expanded our sales and marketing resources to more than 20 full time employees in field sales, sales administration and marketing.

Throughout 2021, additional regulatory approvals were received – a 510(k) clearance for TORRENTX™ in the US, a wound wash that will go to market with Triad Life Sciences in Q2 of 2022, and TGA clearance for XPERIENCE™ in Australia which will also be launched in 2022.

Our core research efforts continued in 2021 and we expanded our patent assets to 42 patents across a range of technologies.

As the year progressed, Next Science faced into a contract dispute with Zimmer, Inc (our Bactisure™ distributor), a wholly owned Zimmer Biomet subsidiary. This dispute was resolved in January of 2022, and we announced the execution of a distribution contract with Zimmer for XPERIENCE™ in the US. The XPERIENCE™ product will be sold through their 2600 hip and knee reconstruction sales force. Zimmer expect to launch in H2 of 2022.

To further strengthen the distribution network for XPERIENCE™, the company granted US distribution rights for plastics and reconstruction to TELA Bio, Inc. This partnership is in line with our strategy to drive wide market adoption across many surgical specialities while expanding our own direct sales force which currently focuses on orthopaedics.

These partnerships provide outstanding representation for XPERIENCE™ in the surgical irrigation market in the US.

Moving into 2022, the rate of adoption of XPERIENCE™ has continued to grow and we now have 100 hospitals online with over 196 surgeons using the product.

A key goal for us now is to move the XPERIENCE™ product into the position of standard of care. To deliver on this, we have a series of clinical studies underway and in planning, designed to provide the evidence needed to support our position as a market leading advanced irrigation brand.

To ensure adequate resources are available to execute on our plans and provide for a very expanded selling network through Zimmer, we successfully undertook a capital raise of A$10M in February 2022 and followed this with a share purchase plan for eligible shareholders.

7. CEO MESSAGE

Outlook

The outlook for Next Science is positive and exciting. We continue to grow our customer base through our presence in the market. With an expanded distribution force, we expect this base to multiply and move to accelerated growth when our planned clinical studies are completed.

Key highlights of our outlook for 2022 include:

- we expect surgery activity to continue to grow back to pre-pandemic levels, increasing demand for our products
- the activation of new arrangements with Zimmer where their 2600 sales force can sell XPERIENCE™ and Bactisure™ and provide a strong, well-connected channel to thousands of joint reconstruction surgeons across the US
- further expansion of the Next Science direct sales team rounding out any coverage gaps and the Next Science marketing and science team leading the messaging and driving the clinical study activity across the US market
- a series of product launches in Australia and New Zealand and then ASEAN

We know the difference our technologies can make in people's lives. I give my sincere thanks to our customers, research partners, business partners, employees, investors and Board of Directors for your roles in supporting the pursuit of our mission of healing patients and saving lives.

Judith Mitchell
CEO and Managing Director

DIRECTORS' REPORT

#NextScienceHeals

The Directors present their report together with the consolidated financial statements of the Group comprising of Next Science Limited (Next Science/Company), and the entities it controlled at the end of, or during, the year ended 31 December 2021 (Group). All amounts are presented in US dollars (USD) unless otherwise stated.

Directors

The Directors of the Company at any time during or since the end of the financial year are:

Mark Compton
Chair

Judith Mitchell
CEO and Managing Director

Bruce Hancox
Non-Executive Director

Daniel Spira
Non-Executive Director

Aileen Stockburger
Non-Executive Director

George Savvides
Chair
Retired 5 May 2021

Dividends

No dividends were paid or declared since the commencement of the year and the Directors do not recommend the declaration of a dividend.

Operating and financial review

Principal activities

The principal activities of the Group during the course of the year were the research, development and commercialisation of technologies which solve issues in human health caused by biofilms. The Company is headquartered in Sydney, Australia and has a research and development centre and sales and marketing functions located in Florida, USA.

Significant changes in the state of affairs and COVID-19 impact

Revenues grew by 160% in 2021 with sales contributions across all of Next Science's products in market and good progress was made in building market awareness for our XBIO™ brand as an answer to the biofilms and bacteria that directly lead to the need for revision (repeat) joint replacement surgeries and for our newly launched product, XPERIENCE™. Revenues showed some early signs of recovery from the negative impacts during 2020 brought about by the COVID-19 shutdown in the USA of elective medical procedures and closure of outpatient wound care clinics. COVID-19 continued to have impact on revenues and establishing relationships with clients, distributors and others in 2021. Whilst COVID-19 is likely to continue to provide a level of disruption during 2022, we expect our customer following to continue to grow across all of our direct product lines as we continue to partner with our customers to provide them with the best tools to serve their patients.

The Group made progress in expanding our addressable market opportunities and taking more direct control of distribution. During March/April 2021, the global distribution rights to BLASTX® transitioned back to Next Science from 3M and Next Science resumed a direct distribution model, selling BLASTX® directly to US hospitals and wound care clinics.

On 23 April 2021, Next Science received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the sale of XPERIENCE™ in the USA and soon thereafter, Next Science began selling XPERIENCE™ directly to US hospitals and Ambulatory Service Centres.

The former Chair of Next Science, George Savvides AM, did not seek re-election at the Company's 2021 Annual General Meeting on 5 May 2021 and retired at the conclusion of the meeting. Mark Compton AM was elected by the Board to the role of Chair thereafter.

On 26 May 2021, Next Science received Therapeutic Goods Administration (TGA) clearance for BLASTX® permitting sales in Australia.

In June 2021, Next Science agreed to open negotiations with Zimmer, Inc (Zimmer), Next Science's distribution partner for the Bactisure product, in relation to the commercialisation and distribution rights to XPERIENCE™. The negotiations followed the filing of a complaint by Zimmer in the United States District Court, Northern District of Indiana, alleging that they had global commercial exclusivity rights over XPERIENCE™. Next Science denied the allegations and advised that it would defend the complaint if and when it was served on Next Science by Zimmer.

Next Science and Zimmer reached agreement in January 2022, in respect of a new US distribution agreement in relation to the supply of a white labelled version of XPERIENCE™ under Zimmer's own labelling (excluding the US plastic reconstructive surgery market which is covered by TELA Bio, Inc's distribution agreement detailed below).

The distribution agreement with Zimmer for XPERIENCE™ has a 5 year term plus a 5 year renewal option and confirms Next Science's intellectual property ownership and rights in respect of XPERIENCE™. In conjunction with the signing of the new distribution agreement, Zimmer withdrew its District Court proceedings. The complaint was dismissed "with prejudice" (meaning that Zimmer cannot reassert the claims) with each party paying its own costs.

Zimmer's joint replacement sales team of approximately 2600 staff are responsible for selling Zimmer's white label version of XPERIENCE™, with Zimmer's US product launch expected in H2 2022. Next Science's commercial team is continuing its own XPERIENCE™ commercialisation efforts as is their partner, TELA Bio, Inc., in the US plastic surgery market with its white labelled product 'Site Guard Surgical Solution'.

On 30 August 2021, Irrimax Corporation, a competitor of Next Science in the wound irrigation sector, served a complaint on Next Science which it had filed in the United States District Court for the Northern District of Georgia alleging common law unfair competition and false advertising regarding XPERIENCE™. Next Science denies the allegations and is vigorously defending Irrimax's complaint.

On 8 November 2021, Next Science received TGA clearance for XPERIENCE™ permitting sales in Australia.

In November 2021, Next Science signed a 10 year exclusive distribution agreement with NASDAQ listed medical technology company, TELA Bio, Inc., in relation to the supply of a white labelled version of Next Science's proprietary XPERIENCE™ across the US plastic reconstructive surgery market.

Operating and financial review (cont.)

Significant changes in the state of affairs and COVID-19 impact (cont.)

TELA Bio, Inc. has begun marketing and selling the white labelled version of XPERIENCE™ under a proprietary brand name – Site Guard Surgical Solution. The agreement includes an annual licensing fee plus transfer price arrangement and minimum purchase amounts that must be met to retain exclusivity.

In the opinion of the Directors, other than the events previously stated, there were no further significant changes in the state of affairs of the Group that occurred during the financial year.

SHAREHOLDER RETURNS

	2021	2020
Revenue	**$8,947,591**	$3,440,975
Loss attributable to owners of the company	**($9,349,639)**	($11,912,004)
Basic earnings per share (EPS) (cents)	**($4.75)**	($6.36)
Share price as at 31 Dec (A$)	**AUD$1.245**	AUD$1.25
Return on capital employed	**(77.8%)**	(59.7%)

Review of operations

The loss for the Group for the financial year to 31 December 2021 after providing for income tax amounted to $9,349,639 (2020: $11,912,004).

Revenue increased by 160% for the period, increasing from $3,440,975 in the prior corresponding period to $8,947,591, reflecting some of the recovery from the impacts of the COVID-19 pandemic during the 2020 financial year across surgical procedures and in wound care clinics.

Gross profit for FY21 was $6,940,122 compared to $2,916,841 in the prior corresponding period. Gross margin as a percent of sales was 78% compared with 85% in the prior corresponding period as a result of a change in composition of revenue.

Selling and distribution expenses were $7,394,871, an increase of $1,724,187 compared with $5,670,684 in the prior corresponding period. The increase in spend in 2021 mainly related to an increase in headcount, with corresponding increases in travel and other employee related expenditure as well as increases in advertising and promotional spend on BLASTX® (associated with the resumption of direct sales of BLASTX® following the termination of the 3M distribution agreement), as well as promotional spend associated with the launch of XPERIENCE™ in April 2021 and the post launch awareness campaign thereafter.

Administration expenses were $4,105,918, an increase of $762,874 compared with $3,343,044 in the prior corresponding period. $524,564 of the increase related to legal fees with the majority of the increase related to defending the legal suits brought by Zimmer, Inc and Irrimax Corporation referred to above.

Research and development expenses were $5,046,875 a decrease of $1,387,539 compared with $6,434,414 in the prior corresponding period. 2020 was a year of significant research and development and regulatory investment to bring XPERIENCE™ through the FDA 510(k) clearance process, with FDA 510(k) clearance being successfully obtained in April 2021.

Cash and cash equivalents at 31 December 2021 amounted to $7,000,869 compared to $8,100,416 at 31 December 2020. Term deposits at 31 December 2021 amounted to $367,129 compared to $7,238,986 at 31 December 2020 as a result of capital raisings in Q4 2020.

Likely developments and expected results of operations

Further information about likely developments in the operations of the Group and the expected results of those operations in future financial years has not been included in this report because disclosure of the information would be likely to result in unreasonable prejudice to the Group.

Matters subsequent to the end of the financial year

As detailed above, in January 2022, Next Science and Zimmer reached agreement in respect of a new US distribution agreement in relation to the supply of a white labelled version of XPERIENCE™ under Zimmer's own labelling (excluding the US plastic reconstructive surgery market which is covered by TELA Bio, Inc's distribution agreement detailed below), and Zimmer withdrew its District Court proceedings.

In conjunction with agreeing the new XPERIENCE™ distribution agreement, Next Science and Zimmer also agreed a refreshed distribution arrangement for Bactisure. The revised Bactisure arrangements include a revised agreement term. The agreement term will end on 31 December 2026 with Zimmer having the option to extend the agreement for an additional five year period by providing 6 months' prior notice.

The Group announced on 23 February 2022 that it was undertaking a capital raising by way of placement and a share purchase plan.

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event, other than those matters detailed above, of a material and unusual nature likely, in the opinion of the directors of the Company, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group, in future financial years.

Environmental regulation

The Group's operations are not subject to significant environment regulations under either Commonwealth or State legislation. The Board believes that the Group has adequate systems in place for the management of environmental requirements.

Government regulation

The Group is subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. In the U.S., the drug, device, diagnostics and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labelling and safety reporting. The exercise of broad regulatory powers available to the U.S. Food and Drug Administration (the "FDA") can result in increases in the amounts of testing and documentation required for FDA clearance of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.

The Group relies on global supply chains, and production and distribution processes that are complex and are subject to lengthy regulatory approval processes and ongoing regulatory requirements which can affect sourcing, supply and pricing of materials used in the Group's products.

Information on Directors

NAME:	MARK COMPTON AM
Title:	Chair and Independent Non-Executive Director
Special Responsibilities:	Member of the Audit and Risk Committee and Member of the People, Culture and Remuneration Committee
Qualifications:	Bachelor of Science (Pharmacology, Physiology and Biochemistry) and an MBA, University of New South Wales. Fellow of the Australian Institute of Company Directors, the Australasian College of Health Services Management and The Australian Institute of Management and the Royal Society (New South Wales).
Experience and expertise:	Mark is Lord Prior of the International Order of St John and Chair of the Board of Trustees of St John International. Mark is Chair of Sonic Healthcare Limited, a global medical diagnostics and healthcare organisation which is a Top 50 ASX listed entity. He is also Chair of St Luke's Care Limited, a not-for-profit health and aged care organisation. Mark has held various CEO and managing director roles, including at St Luke's Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012).
Other current directorships:	Chair and Non-Executive Director of Sonic Healthcare Limited (ASX: SHL). Chair of the Board of Trustees of St John International, Chair of St Luke's Care Limited.
Former listed directorships (last 3 years):	None

8. DIRECTORS' REPORT

NAME:	JUDITH MITCHELL
Title:	Chief Executive Officer and Managing Director
Special Responsibilities:	None
Qualifications:	MBA, University of Hull Graduate of the Australian Institute of Company Directors
Experience and expertise:	Prior to joining Next Science in 2017, Judith served as President of DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson, before which Judith was President of Asia Pacific for Synthes GmbH, the world leaders in orthopaedic trauma care. Judith commenced her medical technology career at GE Medical Systems, where over 14 years, she held positions in sales, marketing and management. She also held a variety of positions at Cochlear Limited in Product Development, Global Marketing and Education.
Other current directorships:	None
Former listed directorships (last 3 years):	None

NAME:	BRUCE HANCOX
Title:	Non-Executive Director
Special Responsibilities:	Chair, Audit and Risk Committee
Qualifications:	Bachelor of Commerce, Canterbury University New Zealand
Experience and expertise:	Bruce has many years of corporate experience across a broad spectrum of commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and Chairman and served on the board of a number of their subsidiaries in New Zealand, Australia and the US. Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation and works with the Walker group of companies to pursue investment opportunities outside the property market.
Other current directorships:	Director of Walker Group Holdings Pty Limited.
Former listed directorships (last 3 years):	Carbonxt Group Limited (ASX:CG1)

Information on Directors (cont.)

NAME:	DANIEL SPIRA
Title:	Independent Non-Executive Director
Special Responsibilities:	Chair, People, Culture and Remuneration Committee
Qualifications:	Bachelor of Commerce, University of New South Wales
Experience and expertise:	Daniel is the CEO of iNova Pharmaceuticals (since 2017) which is a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region. Prior to that, Daniel spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.
Other current directorships:	None
Former listed directorships (last 3 years):	None

NAME:	AILEEN STOCKBURGER
Title:	Independent Non-Executive Director
Special Responsibilities:	Member, Audit and Risk Committee, Member of the People, Culture and Remuneration Committee
Qualifications:	Bachelor of Science and MBA, The Wharton School, University of Pennsylvania, Graduate of the Australian Institute of Company Directors, Certified Public Accountant (CPA – USA).
Experience and expertise:	Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's largest medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena.
Other current directorships:	Non-Executive Director, Microbot Medical Inc. (NASDAQ: MBOT)
Former listed directorships (last 3 years):	None

NAME:	GEORGE SAVVIDES AM (RETIRED 5 MAY 2021)
Title:	Chair and Independent Non-Executive Director
Special Responsibilities:	Member of the Audit and Risk Committee and Member of the People, Culture and Remuneration Committee
Qualifications:	Bachelor of Engineering (Honours), University of New South Wales and MBA, University of Technology, Sydney. Fellow of the Australian Institute of Company Directors.
Experience and expertise:	George has 30 years of experience in the Australian & New Zealand healthcare sector. He was CEO of two successful IPO listings on the ASX, being Sigma in 1999 and Medibank Private in 2014. He served as Medibank CEO for 14 years. George served as Chair of Kings Consolidated Group Pty Ltd (2016 to 2018) and Macquarie University Hospital (2016 to 2018) and retired as Chair of World Vision Australia after 18 years of service in February 2018. He was a board member of the International Federation of Health Plans for 10 years including a period as Deputy President, retiring in 2016.
Other current directorships:	He currently serves as Non-Executive Chair of the public broadcaster, SBS having been appointed a Non-Executive Director in 2017 and Chair in 2020. He is also a Non-Executive Director of IAG (since 2019) and NZX listed Ryman Healthcare, a large residential aged care provider in New Zealand (since 2013).
Former listed directorships (last 3 years):	None

Company Secretary

Gillian Nairn, BA/LLB, LLM, FGIA, has held the role of Company Secretary since 21 June 2018. Gillian is an experienced corporate governance professional with more than 20 years legal and governance experience gained in private practice and in various company secretarial roles, predominantly with listed entities, in a variety of sectors including healthcare, manufacturing, oil and gas, professional services and education.

Meetings of directors

The number of meetings held and attended by each of the Directors of the Company during the year ended 31 December 2021 were as follows:

NAME OF DIRECTOR	BOARD MEETINGS		PEOPLE, CULTURE & REMUNERATION COMMITTEE		AUDIT AND RISK COMMITTEE	
	A	B	A	B	A	B
Mark Compton	19	19	2	2	3	3
Judith Mitchell	19	19	–	–	–	–
Bruce Hancox	19	19	–	–	6	6
Daniel Spira	19	18	2	2	–	–
Aileen Stockburger	19	18	1	1	6	6
George Savvides	7	7	1	1	3	3

A – Number of meetings held when Director was eligible to attend
B – Number of meetings attended during the time the Director held office

Directors' interests

The relevant interest of each Director in shares and options over such instruments issued by the Group, as notified by the Directors to the ASX in accordance with section 205G(1) of the Corporations Act 2001 at the date of this report is as follows:

NAME OF DIRECTOR	FULLY PAID ORDINARY SHARES	SHARE OPTIONS
	Number	Number
Mark Compton	137,438	520,000
Judith Mitchell	6,560,000	-
Bruce Hancox	530,000	520,000
Daniel Spira	723,437	260,000
Aileen Stockburger	44,837	520,000
Total	**7,995,712**	**1,820,000**

Shares under option

At the date of this report, there are 2,890,000 options over ordinary shares on issue (2020: 8,092,500 options), representing 1.46% (2020: 4.17%) of the Company's undiluted total share capital, granted to employees and directors under an equity incentive plan.

Indemnity and insurance of officers

The Group has indemnified the directors and executives of the Group for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Group has paid a premium in respect of a contract to insure the directors and executives of the Company against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

Indemnity and insurance of auditor

The Company and the Group have not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

Proceedings on behalf of the company

No person has applied to a court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Non-audit services

Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor are outlined in note 30 to the financial statements.

The Directors are satisfied that the provision of non-audit services by the auditor during the financial year is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*.

The Directors are of the opinion that the services as disclosed in note 30 to the financial statements do not compromise the external auditor's independence requirements under the Corporations Act 2001 for the following reasons:

- All non-audit services have been reviewed and approved to ensure that they do not impact the integrity and objectivity of the auditor; and
- None of the services undermine the general principles relating to auditor independence set out in APES 110 Code of Ethics for Professional Accountants (including Independence Standards) issued by the Accounting Professional and Ethical Standards Board, including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for the Company, acting as advocate for the Company or jointly sharing economic risks and rewards.

Officers of the Company who are former partners of KPMG

No officer of the Company was an audit partner of KPMG, being the auditors during the financial year, at a time when the audit firm undertook an audit of the Company.

Auditor's independence declaration

The auditor's independence declaration is set out on page 40 and forms part of the Directors' Report for the financial year ended 31 December 2021.

Auditor

KPMG continues in office in accordance with section 327 of the *Corporations Act 2001*.

Remuneration Report (audited)

This Remuneration Report forms part of the Directors' Report for the year ended 31 December 2021. This Report outlines the details of the remuneration arrangements for the key management personnel of the Group, including remuneration strategy, framework and practices, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

Remuneration Report (audited) (cont.)

For the purposes of this Report, key management personnel (KMP) are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly or indirectly, including any Director of the Company (non-executive or executive).

The information in this Remuneration Report is set out under the following headings:

- Key management personnel (KMP)
- Remuneration governance
- Service agreements and remuneration policy
- Non-Executive Directors' remuneration
- Employee incentive arrangements and link between performance and reward
- Share option plans and performance rights over equity instruments
- KMP Remuneration
- KMP Equity Holdings

Key management personnel (KMP)

The KMP of the Group during the financial year and the positions held are summarised below:

Non-Executive Directors

Mark Compton	
Bruce Hancox	
Daniel Spira	
Aileen Stockburger	
George Savvides	*Retired 5 May 2021*

CEO and Managing Director

Judith Mitchell

Other KMP

Jacqueline Butler	*Chief Financial Officer*
Matthew Myntti	*Chief Technology Officer*
Jon Swanson	*Chief Operating Officer*
Dustin Haines	*Chief Commercial Officer*

Remuneration governance

The People, Culture and Remuneration Committee currently comprises of:

Daniel Spira (Chair)
Mark Compton
Aileen Stockburger

The role and responsibilities, composition, structure and membership requirements of the People, Culture and Remuneration Committee are documented in the People, Culture and Remuneration Committee Charter available at www.nextscience.com/corp-governance.

The People, Culture and Remuneration Charter provides that the Committee should comprise at least three members, all of whom are Non-Executive Directors and a majority of whom are independent Directors.

The Chair of the Committee should be an independent Director who is not Chair of the Board.

The Charter requires the Committee to meet at least twice each year.

All of the current members of the People, Culture and Remuneration Committee have been assessed by the Board as being independent Non-Executive Directors and the Chair of the Committee is not Chair of the Board.

Service agreements and remuneration policy

Executives are employed under executive employment agreements with the Group.

In determining remuneration, the Group considers:

- industry based remuneration benchmaking (Australia and USA);
- market developments affecting remuneration practices;
- the remuneration expectations of an executive whom the Company wants to employ;
- future outlook for the Group and market generally;
- the Company's performance over a performance period; and
- the link between remuneration and the successful implementation of the Company's strategy and achievement of strategic objectives.

Executive incentives comprise fixed and variable elements linked to Company and individual performance as detailed in this Report.

Employment Agreements

NAME:	JUDITH MITCHELL
Title:	CEO and Managing Director
Details:	Ongoing service agreement inclusive of superannuation and to be reviewed annually by the Company. The Company may terminate the service agreement: i. by giving a 3-month termination notice; or ii. without notice, in the event of serious misconduct or for any other reason that enables summary dismissal at law. Judith is entitled to participate in the Company's short-term and long-term incentive plans.

NAME:	JACQUELINE BUTLER
Title:	Chief Financial Officer (CFO)
Details:	Ongoing service agreement inclusive of superannuation and to be reviewed annually by the Company. The Company may terminate the service agreement: i. by giving a 3-month termination notice; or ii. without notice, in the event of serious misconduct or for any other reason that enables summary dismissal at law. Jacqueline is entitled to participate in the Company's short-term and long-term incentive plans.

Employment Agreements

NAME:	DR. MATTHEW MYNTTI
Title:	Chief Technology Officer (CTO)
Details:	Ongoing employment agreement to be reviewed annually by the Company. The Company may terminate the employment agreement: i. by giving 90 days written notice; or ii. without notice, in the event of serious misconduct or for any other reason that enables summary dismissal at law. Matthew is entitled to participate in the Company's short-term and long-term incentive plans.

NAME:	JON SWANSON
Title:	Chief Operating Officer (COO)
Details:	Ongoing employment agreement to be reviewed annually by the Company. The Company may terminate the employment agreement: i. by giving 90 days written notice; or ii. without notice, in the event of serious misconduct or for any other reason that enables summary dismissal at law. Jon is entitled to participate in the Company's short-term and long-term incentive plans.

NAME:	DUSTIN HAINES
Title:	Chief Commercial Officer (CCO)
Details:	Ongoing employment agreement to be reviewed annually by the Company. The Company may terminate the employment agreement: i. by giving 90 days written notice; or ii. without notice, in the event of serious misconduct or for any other reason that enables summary dismissal at law. Dustin is entitled to participate in the Company's short-term and long-term incentive plans.

8. DIRECTORS' REPORT

Non-Executive Directors' Remuneration

Each of the Non-Executive Directors have entered into appointment letters with Next Science confirming the terms of their appointment and their roles and responsibilities.

Under the Constitution, the Board decides the amount paid to each Non-Executive Director as remuneration for their services as a Director. However, the Constitution and the ASX Listing Rules stipulate that the total amount of fees paid to Non-Executive Directors (excluding any special exertion fees) must not exceed the amount approved by the Company's shareholders. This amount has been fixed initially in the Company's Constitution at A$750,000 per annum and may only be varied by ordinary resolution in general meeting.

The annual fee for Non-Executive Directors is AUD$90,000 per annum (inclusive of superannuation) and for the Chair is AUD$250,000 per annum (inclusive of superannuation). The Chair's fees reflect the additional responsibilities of the role. An additional fee of AUD$10,000 per annum is paid for performing the role of Chair of the Audit and Risk Committee or People, Culture and Remuneration Committee. The Company paid special exertion fees to Aileen Stockburger during 2021. These exertions were to assist the Board in ensuring the Company's activities in the US received appropriate oversight and support whilst the Managing Director was unable to visit the US due to COVID-19 travel and isolation restrictions.

Employee incentive arrangements and link between performance and reward

Short-Term Incentive (STI) Plan for Executives

The Managing Director, CFO, CTO and COO were invited to participate in the Company's short-term incentive plan (STI Plan), effective from the Company's admission to the ASX in April 2019. The CCO was invited to participate in the STI plan following his appointment in June 2020.

Participants in the STI Plan, must be employed with the Company, or wholly owned subsidiary of the Company, for at least six months during the Plan year and still be employed until after the announcement of the Group's results to the ASX following the relevant Plan year. Participation is by invitation from the Board and is not automatic. Participants who resign or are terminated before the end of a Plan year are not eligible for any payments under the Plan unless the Board determines otherwise, in its sole discretion.

The STI plan objectives are to:

- reward executives for their contribution in ensuring that the Group achieves its annual financial performance targets;
- enhance the Group's opportunity to attract, motivate and retain high calibre and high performing executives; and
- link part of executive remuneration directly to the achievement of the Group and individual KPIs.

The making of any payment under the STI Plan is subject to the achievement of three gateway hurdles; at least 90% of a base consolidated revenue target; 100% of a base consolidated EBITDA target; and an individual performance rating of a least 3 out of 5.

The maximum STI opportunity is 100% of Total Fixed Remuneration (TFR) for the Managing Director and 80% of TFR for the CFO, CTO, COO and CCO. To receive the maximum STI opportunity, executives must achieve performance targets for consolidated revenue, consolidated EBITDA and individual performance.

As a number of the members of the executive team already have significant security holdings in Next Science, any payments under the STI Plan will be paid in cash to ensure that the STI opportunities operate as true incentives.

No STI payments were made in respect of the financial year ended 31 December 2021 (2020: Nil) as revenue and EBITDA targets were not achieved.

Employee incentive arrangements and link between performance and reward (cont.)

Long-Term Incentive (LTI) Plan for Executives

At the time of the Company's IPO in April 2019, the Board of the Company established a long-term incentive plan under which incentives are issued in the form of Performance Rights to eligible participants (LTI Plan).

The Managing Director, CFO, CTO, CCO and COO are entitled to participate in the LTI Plan. If Group performance hurdles are achieved in the financial year ending 31 December 2022, and thereafter, the Managing Director has the opportunity to be granted performance rights worth 200% of her Total Fixed Remuneration (TFR) and the other participants in the LTI Plan have the opportunity to be granted performance rights worth 150% of their TFR.

The number of Performance Rights granted will be based on the volume weighted average price (VWAP) of shares in the Company for the period 1 January until the day before the release on ASX of the Company's relevant preliminary full year results.

The vesting of Performance Rights issued under the LTI Plan is dependent on satisfaction of the following vesting conditions:

- 50% of Performance Rights will vest if the compound annual TSR is at least 15% per annum; and
- 100% of Performance Rights will vest if the compound annual TSR is at least 30% per annum.

If compound TSR is less than 15% per annum, no Performance Right will vest.

Subject to vesting conditions being satisfied, Performance Rights automatically convert to shares, on a one-for one basis, three years after the date on which they are granted. If vesting conditions have not been satisfied, the Performance Rights will automatically lapse. Participants must be employed by the Company or a wholly owned subsidiary at the date of vesting.

No Performance Rights have been issued in relation to the financial year ending 31 December 2021 (2020: Nil) as vesting conditions were not met.

The Company's LTI Plan will operate in future years with grants based on the relevant revenue and/or other Group performance measures. It is not intended to change the size of the grant to participants or the vesting conditions.

In recognition of the CCO's extensive work in 2020 to prepare the Company for the launch of XPERIENCE™ in 2021, and to provide longer term upside opportunity to the CCO similar to that available to the other executive KMPs from the options awarded to them prior to the Company's admission to ASX, in February 2021, the Company granted the CCO USD$315,000 worth of performance rights. The vesting of the CCO's performance rights was subject to continued tenure and was to be over three years with 1/3 vesting in 1 year, 1/3 in 2 years and 1/3 in 3 years from the grant date. However, due to employment ceasing on 20 April 2022 the performance rights in year 2 and 3 will not vest.

Options and rights over equity instruments

Prior to the Company being admitted to the ASX, the Group established an Equity Incentive Plan (ECP) for US employees and an Employee Share Option Plan (ESOP) for Australian employees and directors (see note 27). With the exception of the CEO and Managing Director, Judith Mitchell, as described below, the only vesting condition applicable to the options granted under these earlier plans was that the individual be employed by the Company, or any wholly owned subsidiary of the Company at the vesting date.

There were no options over ordinary shares issued as compensation to KMP during the year ended 31 December 2021 (2020: Nil). Details of the options over ordinary shares issued under the ECP or ESOP which were held by KMP as at 31 December 2021 are set out on the following page:

KMP	GRANT DATE	EXPIRY DATE	VESTING DATE	FAIR VALUE AT GRANT DATE		EXERCISE PRICE (USD)
Non-Executive Directors				*Pre-share Split (USD)*	*Post-share Split (USD)*	
Mark Compton	17-Dec-2018	17-Dec-2023	17-Dec-2021	2,138	0.33	0.56
Bruce Hancox	17-Dec-2018	17-Dec-2023	17-Dec-2021	2,138	0.33	0.56
Daniel Spira	17-Dec-2018	17-Dec-2023	17-Dec-2021	2,138	0.20	0.56
Aileen Stockburger	17-Dec-2018	17-Dec-2023	17-Dec-2021	2,138	0.33	0.56
Other KMP						
Jon Swanson	17-Dec-2018	17-Dec-2023	17-Dec-2020	2,138	0.33	0.56

There were 340,602 rights over ordinary shares issued as compensation to KMP during the year ended 31 December 2021 (2020: Nil). There were no previous rights issues.

KMP	NUMBER OF RIGHTS GRANTED	GRANT DATE	EXPIRY DATE	VESTING CONDITION	FAIR VALUE AT GRANT DATE
Other KMP					
Dustin Haines	340,602	22-Feb-2021	22-Feb-2024	Continued employment	0.92

The rights were to vest over three years with 1/3 vesting after 1 year, 1/3 after 2 years and 1/3 after 3 years from the grant date. However, due to employment ceasing on 20 April 2022 the performance rights in year 2 and 3 will not vest.

The movement for the year ended 31 December 2021, in the number of rights and options over ordinary shares in Next Science Limited held, directly, indirectly or beneficially, by each KMP, including their related parties was as follows:

KMP	BALANCE AS AT 1 JAN 2021 No.	GRANTED No.	EXERCISED No.	LAPSED No.	BALANCE AS AT 31 DEC 2021 No.	VESTED DURING THE YEAR	VESTED AND EXERCISABLE No.	UN-VESTED No.
Executive Director								
Judith Mitchell	2,340,000	–	(1,560,000)	(780,000)	–	–	–	–
Non-Executive Directors								
George Savvides	650,000	–	–	(650,000)	–	–	–	–
Bruce Hancox	520,000	–	–	–	520,000	520,000	520,000	–
Daniel Spira	1,300,000	–	(1,040,000)	–	260,000	260,000	260,000	–
Mark Compton	520,000	–	–	–	520,000	520,000	520,000	–
Aileen Stockburger	520,000	–	–	–	520,000	520,000	520,000	–
Other KMP								
Matthew Myntti	–	–	–	–	–		–	–
Jon Swanson	650,000	–	–	–	650,000		650,000	–
Jacqueline Butler	650,000	–	(650,000)	–	–	–	–	–
Dustin Haines	–	–	–	–	–	–	–	–
Rights								
Dustin Haines	–	340,602	–	–	340,602	–	N/A	340,602

Options and rights over equity instruments (cont.)

The movement for the year ended 31 December 2020, by number options over ordinary shares in Next Science Limited held, directly, indirectly or beneficially, by each KMP, including their related parties was as follows:

KMP	BALANCE AS AT 1 JAN 2020 No.	GRANTED No.	EXERCISED No.	LAPSED No.	BALANCE AS AT 31 DEC 2020 No.	VESTED AND EXERCISABLE No.	UN-VESTED No.
Executive Director							
Judith Mitchell	2,340,000	–	–	–	2,340,000	1,560,000	780,000
Non-Executive Directors							
George Savvides	650,000	–	–	–	650,000	–	650,000
Bruce Hancox	520,000	–	–	–	520,000	–	520,000
Daniel Spira	1,300,000	–	–	–	1,300,000	1,040,000	260,000
Mark Compton	520,000	–	–	–	520,000	–	520,000
Aileen Stockburger	520,000	–	–	–	520,000	–	520,000
Other KMP							
Matthew Myntti	–	–	–	–	–	–	–
Jon Swanson	650,000	–	–	–	650,000	650,000	–
Jacqueline Butler	650,000	–	–	–	650,000	650,000	–
Dustin Haines	–	–	–	–	–	–	–

Exercise of options granted as compensation

During the reporting period, there were 3,250,000 shares issued upon the exercise of options previously granted as compensation, to KMP:

USD	NUMBER OF SHARES	AMOUNT PAID $/SHARE	VALUE OF OPTIONS EXERCISED $ (I)	VALUE OF SHARES RECEIVED UPON EXERCISE OF OPTIONS $
Judith Mitchell	1,560,000	0.42	913,941	1,569,141
Daniel Spira	1,040,000	0.42	703,870	1,140,670
Jacqueline Butler	650,000	0.42	439,918	712,918

i. The value of the options exercised during the year is calculated as the market price of shares of the Company as at the close of trading on the date the options were exercised less the price paid to exercise the option.

ii. There are no amounts unpaid on the shares issued as a result of the exercise of the options in the 2021 financial year. There were no other share options held by KMP granted, exercised or lapsed during the reporting period other than as disclosed above.

Analysis of movements in options and performance rights

The value of rights or options over ordinary shares in the Company granted and exercised by each KMP during the reporting period is detailed below.

KMP	GRANTED IN YEAR $ (I)	VALUE OF RIGHTS OR OPTIONS EXERCISED IN YEAR $ (II)
Judith Mitchell	–	913,941
Daniel Spira	–	703,870
Jacqueline Butler	–	439,918
Dustin Haines	315,000	-

i. The value of rights granted during the financial year is the fair value of the rights calculated at grant date. The total value of the rights granted is included in the table above. This amount is allocated to remuneration over the vesting period.

ii. The value of options exercised during the year is calculated as the market price of shares of the Company as at the close of trading on the date the options were exercised less the price paid to exercise the options.

Details of equity incentives affecting current and future remuneration

KMP	INSTRUMENT	NUMBER	GRANT DATE	% VESTED IN YEAR	FINANCIAL YEARS IN WHICH GRANT VESTS
Non-Executive Directors					
Mark Compton	Options	520,000	17-Dec-2018	100%	2021
Bruce Hancox	Options	520,000	17-Dec-2018	100%	2021
Aileen Stockburger	Options	520,000	17-Dec-2018	100%	2021
Daniel Spira	Options	260,000	17-Dec-2018	100%	2021
Other KMP					
Jon Swanson	Options	650,000	17-Dec-2018	100%	2020
Dustin Haines	Rights	113,534	22-Feb-2021	–%	2022
Dustin Haines	Rights	–	22-Feb-2021	–%	2023
Dustin Haines	Rights	–	22-Feb-2021	–%	2024

KMP Remuneration

The table below details the remuneration of the KMP based on the remuneration policies discussed in this report for the year ended 31 December 2021.

Year ended 31 December 2021

KMP (USD)	CASH SALARY AND FEES (i)	OTHER CASH SERVICE (ii)	LONG SERVICE LEAVE	SUPER-ANNUATION	SHARE-BASED PAYMENTS		TOTAL	PERFORMANCE RELATED (V)
					Options (iii)	*Rights (iv)*		
	$	$	$	$	$	$	$	%
Executive Director								
Judith Mitchell	283,239	–	3,696	17,051	(101,211)	–	202,775	–
Non-Executive Directors								
Mark Compton	144,570	–	–	–	71,729	–	216,299	–
Bruce Hancox	68,388	–	–	6,663	71,729	–	146,780	–
Daniel Spira	73,385	–	–	1,667	35,865	–	110,917	–
Aileen Stockburger	83,860	–	–	–	71,729	–	155,589	–
George Savvides	66,493	–	–	–	(132,471)	–	(65,978)	–
Other KMP								
Matthew Myntti	350,000	6,516	–	–	–	–	356,516	–
Jon Swanson	254,155	651	–	–	–	–	254,806	–
Jacqueline Butler	198,231	–	3,126	16,990	–	–	218,347	–
Dustin Haines	320,235	106	–	–	–	96,250	416,591	–
	1,842,556	7,273	6,822	42,371	17,370	96,250	2,012,642	

i. On 5 May 2021, George Savvides, AM retired as Chair and Mark Compton assumed the role of Chair.

ii. Other cash service includes motor vehicle allowance and/or other minor benefits. For the year ended 31 December 2021 threshold Group performance targets were not met and hence no amounts were awarded to KMP under the STI Plan.

iii. The value of the share options granted to KMP is calculated at the grant date using the Black-Scholes formula. This value is allocated to each reporting period evenly over the period from grant date to vesting date. The value disclosed is the portion of the fair value of the options recognised as an expense in each reporting period. Certain tranches of previous options awarded did not vest and lapsed during the year as vesting conditions were not met. In accordance with Australian Accounting Standards previous expenses related to the lapsed portion of options were reversed in the current year.

iv. The fair value of the right is calculated at the date of grant using the 60 day volume weighted average price of Next Science shares in the period immediately prior to the offer date. The rights disclosed is the portion of the fair value of the rights recognised as an expense in the reporting period.

v. Disclosed above are the relative proportions of each individual's remuneration that are related to performance; the remaining proportion being fixed remuneration.

KMP Remuneration (cont.)

The table below details the remuneration of KMP for the year ended 31 December 2020.

Year ended 31 December 2020

KMP (USD)	CASH SALARY AND FEES(i)	OTHER CASH SERVICE (ii)(iii)	LONG SERVICE LEAVE	SUPER-ANNUATION	SHARE-BASED PAYMENTS		TOTAL	PERFORMANCE RELATED (VI)
					Options (iv)	*Shares in lieu of fees (v)*		
	$	$	$	$	$	$	$	%
Executive Director								
Judith Mitchell	261,606	–	3,038	14,676	960	–	280,280	–
Non-Executive Directors								
George Savvides	161,960	–	–	10,771	69,878	–	242,609	–
Bruce Hancox	63,098	–	–	5,994	55,902	–	124,994	–
Daniel Spira	51,302	–	–	1,421	27,951	15,547	96,221	–
Mark Compton	62,183	–	–	–	55,902	–	118,085	–
Aileen Stockburger	48,810	–	–	–	55,902	13,992	118,704	–
Other KMP								
Matthew Myntti	350,000	–	–	–	–	–	350,000	–
Jon Swanson	250,000	–	–	–	115,338	–	365,338	–
Jacqueline Butler	171,124	–	1,985	14,751	–	–	187,860	–
Dustin Haines	173,250	20,879	–	–	–	–	194,129	–
	1,593,333	20,879	5,023	47,613	381,833	29,539	2,078,220	

i. Dustin Haines was appointed Chief Commercial Officer and commenced employment on 10 June 2020. Mr Haines' employment will end on 20 April 2022.

ii. For the year ended 31 December 2020 threshold Group performance targets were not met and hence no amounts were awarded to KMP under the STI Plan.

iii. Other cash benefits include an amount of $20,879 for relocation expenses paid to Dustin Haines as part of the arrangements agreed in respect of his engagement.

iv. The value of the share options granted to KMP is calculated at the grant date using the Black-Scholes formula. This value is allocated to each reporting period evenly over the period from grant date to vesting date. The value disclosed is the portion of the fair value of the options recognised as an expense in each reporting period.

v. Amounts included under share-based payments for Daniel Spira and Aileen Stockburger are in relation to shares paid in lieu of their Director fees. The Company received a waiver from the ASX that in respect of ASX Listing Rule 10.11 to allow Aileen and Daniel, as Non-Executive Directors, to elect to be issued shares in lieu of their fees for the first 12 months after the Company's admission to the ASX.

vi. Disclosed above are the relative proportions of each individual's remuneration that are related to performance; the remaining proportion being fixed remuneration.

KMP Equity Holdings

The movement during the reporting period in the number of shares in Next Science Limited held directly, indirectly or beneficially, by each KMP, including their related parties, is as follows:

Year ended 31 December 2021

KMP	BALANCE AS AT 1 JAN 2021 No.	RECEIVED ON EXERCISE OF OPTIONS No.	OTHER CHANGES DURING THE YEAR No.*	BALANCE AS AT 31 DEC 2021 No.
Executive Director				
Judith Mitchell	5,000,000	1,560,000	–	6,560,000
Non-Executive Directors				
Mark Compton	137,438	–	–	137,438
Bruce Hancox	530,000	–	–	530,000
Daniel Spira	49,266	1,040,000**	(365,829)	723,437
Aileen Stockburger	44,837	–	–	44,837
George Savvides	649,876	–	(180,000)	469,876
Other KMP				
Matthew Myntti	20,657,000	–	(7,302,011)***	13,354,989
Jon Swanson	70,000	–	(20,000)	50,000
Jacqueline Butler	–	650,000**	(239,804)	410,196
Dustin Haines	–	–	–	–

* Other changes represent shares that were purchased, sold or transferred to another party during the year.

** In respect of these options, in order to facilitate the exercise of these options the Company provided a short term loan to the option holder which was repaid within 15 days.

*** As announced to ASX on 6 September 2021

KMP Equity Holdings (cont.)

Year ended 31 December 2020

KMP	BALANCE AS AT 1 JAN 2020 No.	RECEIVED ON EXERCISE OF OPTIONS No.	SHARES RECEIVED IN LIEU OF DIRECTORS FEES No. (i)	OTHER CHANGES DURING THE YEAR No.*	BALANCE AS AT 31 DEC 2020 No.
Executive Director					
Judith Mitchell	4,732,000	–	–	268,000	5,000,000
Non-Executive Directors					
George Savvides	625,000	–	–	24,876	649,876
Bruce Hancox	–	–	–	530,000	530,000
Daniel Spira	36,729	–	12,537	–	49,266
Mark Compton	125,000	–	–	12,438	137,438
Aileen Stockburger	33,554	–	11,283	–	44,837
Other KMP					
Matthew Myntti	20,657,000	–	–	–	20,657,000
Jon Swanson	70,000	–	–	–	70,000
Jacqueline Butler	–	–	–	–	–
Dustin Haines	–	–	–	–	–

* Other changes represent shares that were purchased during the year.

i. The Company was granted a waiver from Listing Rule 10.11 to the extent necessary to permit the Company to issue shares without shareholder approval to Non-Executive Directors, Aileen Stockburger and Daniel Spira, in lieu of director fees for the first 12 months after the Company's admission to the official list of the ASX. The shares issued were fully paid ordinary shares in the capital of the Company on the same terms and conditions as the Company's existing shares and were issued at the Offer Price of A$1 for the first quarter after admission. For later quarters, the shares were issued at the 10 day Volume Weighted Average Price (VWAP) of the Company's shares for the first 10 trading days of the relevant quarter.

This concludes the remuneration report (audited).

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors:

Mark Compton AM
Chair

Dated at Sydney this 23rd day of February 2022

LEAD AUDITOR'S INDEPENDENCE DECLARATION

#NextScienceHeals

9. LEAD AUDITOR'S INDEPENDENCE DECLARATION

KPMG

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of Next Science Limited

I declare that, to the best of my knowledge and belief, in relation to the audit of Next Science Limited for the financial year ended 31 December 2021 there have been:

i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and

ii. no contraventions of any applicable code of professional conduct in relation to the audit.

KPMG

KPMG

Tony Nimac
Partner

Sydney

23 February 2022

10. CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the Year Ended 31 December 2021

IN USD	NOTES	2021	2020
		$	*$*
Revenue	5	**8,947,591**	3,440,975
Cost of sales		**(2,007,469)**	(524,134)
Gross profit		**6,940,122**	2,916,841
Other income	5	**147,112**	356,574
Selling and distribution expenses		**(7,394,871)**	(5,670,684)
Research and development expenses		**(5,046,875)**	(6,434,414)
Administration expenses		**(4,105,918)**	(3,343,044)
Other expenses	7	**(15,633)**	(13,352)
Operating loss		**(9,476,063)**	(12,188,079)
Finance income	9	**142,900**	297,254
Finance costs	10	**(16,476)**	(21,179)
Net finance income		**126,424**	276,075
Loss before income tax		**(9,349,639)**	(11,912,004)
Income tax expense	11	**–**	–
Loss for the year		**(9,349,639)**	(11,912,004)
Other comprehensive income, net of income tax			
Foreign currency translation differences for foreign operations		**(547,407)**	396,838
Total comprehensive loss for the year		**(9,897,046)**	(11,515,166)
Earnings per share			
From continuing operations		*Cents*	*Cents*
Basic earnings	31	(4.75)	(6.36)
Diluted earnings	31	(4.75)	(6.36)

The accompanying notes form part of these financial statements.

11. CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2021

IN USD	NOTES	2021	2020
ASSETS **Current assets**		*$*	*$*
Cash and cash equivalents	12	**7,000,869**	8,100,416
Trade and other receivables	13	**887,211**	3,388,045
Inventories	14	**1,500,522**	1,071,979
Other current assets - term deposits	15	**367,129**	7,238,986
Other current assets - other	15	**476,049**	452,458
Total current assets		**10,231,780**	20,251,884
Non-current assets			
Trade and other receivables	13	**36,656**	36,656
Property, plant and equipment	16	**683,562**	788,133
Intangible assets	17	**2,532,491**	2,334,936
Right-of-use assets	18	**232,456**	227,265
Total non-current assets		**3,485,165**	3,386,990
Total assets		**13,716,945**	23,638,874
LIABILITIES **Current liabilities**			
Trade and other payables	19	**1,172,996**	1,064,365
Contract liabilities	20	**91,177**	1,909,554
Lease liabilities	21	**166,235**	170,946
Employee benefits	22	**109,611**	81,231
Total current liabilities		**1,540,019**	3,226,096
Non-current liabilities			
Contract liabilities	20	**1,283,334**	1,374,510
Lease liabilities	21	**109,802**	115,889
Employee benefits	22	**17,295**	9,385
Total non-current liabilities		**1,410,431**	1,499,784
Total liabilities		**2,950,450**	4,725,880
Net assets		**10,766,495**	18,912,994
Equity			
Share capital	23	**102,921,007**	101,281,467
Common control reserve	23	**(42,596,715)**	(42,596,715)
Foreign currency translation reserve	23	**(1,349,143)**	(801,736)
Share option reserve	23	**2,140,298**	2,125,541
Performance rights reserve		**96,250**	–
Accumulated losses	23	**(50,445,202)**	(41,095,563)
Total equity		**10,766,495**	18,912,994

The accompanying notes form part of these financial statements.

12. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the Year Ended 31 December 2021

2021 IN USD	SHARE CAPITAL	COMMON CONTROL RESERVE	FOREIGN CURRENCY TRANSLATION RESERVE	SHARE OPTION RESERVE	PERFORMANCE RIGHTS RESERVE	ACCUMULATED LOSSES	TOTAL EQUITY
	$	$	$	$		$	$
Balance at 1 January 2021	**101,281,467**	**(42,596,715)**	**(801,736)**	**2,125,541**	**–**	**(41,095,563)**	**18,912,994**
Loss for the year	–	–	–	–	–	(9,349,639)	(9,349,639)
Other comprehensive income							
Foreign currency translation differences	–	–	(547,407)	–	–	–	(547,407)
Total other comprehensive income	–	–	(547,407)	–	–	–	(547,407)
Total comprehensive loss for the year	–	–	(547,407)	–	–	(9,349,639)	(9,897,046)
Transactions with owners in their capacity as owners							
Share-based payments	–	–	–	17,370	96,250	–	113,620
Foreign exchange impact	–	–	–	(2,613)	–	–	(2,613)
Issue of ordinary shares	1,645,770	–	–	–	–	–	1,645,770
Capital raising costs	(6,230)	–	–	–	–	–	(6,230)
Total transactions with owners	1,639,540	–	–	14,757	96,250	–	1,750,547
Balance at 31 December 2021	**102,921,007**	**(42,596,715)**	**(1,349,143)**	**2,140,298**	**96,250**	**(50,445,202)**	**10,766,495**

The accompanying notes form part of these financial statements.

12. CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the Year Ended 31 December 2021

2020 IN USD	SHARE CAPITAL	COMMON CONTROL RESERVE	FOREIGN CURRENCY TRANSLATION RESERVE	SHARE OPTION RESERVE	ACCUMULATED LOSSES	TOTAL EQUITY
	$	$	$	$	$	$
Balance at 1 January 2020	**90,693,590**	**(42,596,715)**	**(1,198,574)**	**1,648,704**	**(29,183,559)**	**19,363,446**
Loss for the year	–	–	–	–	(11,912,004)	(11,912,004)
Other comprehensive income						
Foreign currency translation differences	–	–	396,838	–	–	396,838
Total other comprehensive income	–	–	396,838	–	–	396,838
Total comprehensive loss for the year	–	–	396,838	–	(11,912,004)	(11,515,166)
Transactions with owners in their capacity as owners						
Share-based payment	–	–	–	482,973	–	482,973
Foreign exchange impact	–	–	–	(6,136)	–	(6,136)
Issue of ordinary shares	11,175,615	–	–	–	–	11,175,615
Conversion of partly paid shares to ordinary shares	(199,999)	–	–	–	–	(199,999)
Capital raising costs	(387,739)	–	–	–	–	(387,739)
Total transactions with owners	10,587,877	–	–	–	–	11,064,714
Balance at 31 December 2020	**101,281,467**	**(42,596,715)**	**(801,736)**	**2,125,541**	**(41,095,563)**	**18,912,994**

The accompanying notes form part of these financial statements.

13. CONSOLIDATED STATEMENT OF CASH FLOWS

For the Year Ended 31 December 2021

IN USD	NOTES	2021	2020
Operating Activities		$	$
Receipts from customers		**9,512,635**	2,950,430
Payments to suppliers and employees		**(16,268,131)**	(12,210,609)
Payments for research and development		**(1,672,278)**	(3,119,907)
Interest received		**16,515**	117,735
COVID 19 government assistance and other income		**146,905**	355,707
Net cash used in operating activities	12	**(8,264,354)**	(11,906,644)
Investing Activities			
Payments for property, plant and equipment	16	**(140,492)**	(213,244)
Payments for intangible assets	17	**(576,266)**	(473,555)
Net cash used in investing activities		**(716,758)**	(686,799)
Financing Activities			
Proceeds from issue of ordinary shares	23	**–**	10,831,275
Proceeds from conversion of options to ordinary shares	23	**1,645,770**	489,125
Capital raising costs		**(6,230)**	(387,740)
Payment of lease liabilities		**(212,759)**	(222,609)
Net cash provided by financing activities		**1,426,781**	10,710,051
Net (decrease) / increase in cash and cash equivalents held		**(7,554,331)**	(1,883,392)
Cash and cash equivalents at beginning of year		**15,339,402**	16,910,605
Effects of exchange rate changes on cash and cash equivalents		**(417,073)**	312,189
Cash and cash equivalents at end of the year (including bank term deposits)		**7,367,998**	15,339,402
Less bank term deposits classified as other current assets	15	**(367,129)**	(7,238,986)
Cash and cash equivalents at end of the year	12	**7,000,869**	**8,100,416**

The accompanying notes form part of these financial statements.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Year Ended 31 December 2021

1. Corporate Information

Next Science Limited (the "Company") is a company domiciled in Australia.

The Group is a for profit entity and primarily involved in the research, development and commercialisation of technologies which solve bacterial related issues.

These consolidated financial statements comprise the Company and its subsidiaries (collectively the "Group" and individually "Group companies") for the year ended 31 December 2021 and comparative information for the year ended 31 December 2020.

2. Basis of Preparation

a. Statement of compliance

The consolidated financial statements are general purpose financial statements which have been prepared in accordance with accounting standards adopted by the Australian Accounting Standards Board ("AASB") and the Corporations Act 2001. The consolidated financial statements comply with International Financial Reporting Standards ("IFRS") adopted by the International Accounting Standards Board ("IASB").

The financial statements were approved by the Board of Directors and authorised for issue on 23 February 2022.

b. Basis of measurement

The financial statements have been prepared on a historical cost basis unless otherwise stated.

c. Functional and presentation currency

The financial statements are presented in United States Dollars, which is the Group's presentation currency. Entities within the Group hold functional currencies of AUD or USD as appropriate to the individual entity.

d. Use of judgements and estimates

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income, expenses and disclosure of contingent liabilities. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

The key judgements, estimates and assumptions are discussed below:

Impairment of non-financial assets

The Group assesses impairment of non financial assets at each reporting date by evaluating conditions specific to the Group and to the particular asset that may lead to impairment. This involves value in use calculations, which incorporate a number of key estimates and assumptions.

Recoverable amount being the net amount of discounted future cash flows materially exceeds the carrying value of non current assets. The recoverable amount of these cash generating units, at balance date, was estimated based on its value in use.

Value in use for the cash-generating units ('CGU') was determined by discounting the future cashflows to be generated from the CGUs and is based on the following key assumptions:

d. Use of judgements and estimates (cont.)

- Cashflows were projected based on forecast operating results over a 5 year period plus a terminal value.
- Average annual revenue growth rates and approved budgets were used for revenue projections.
- Discount rate of 12% based on the weighted average cost of capital.
- Changes in key assumptions would impact recoverable amount calculations

Estimation of useful lives of assets

The consolidated entity determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non strategic assets that have been abandoned or sold will be written off or written down and the incremental borrowing rate is estimated.

Recovery of deferred tax assets

Deferred tax assets for tax losses are only recognised if the Group considers it is probable that future taxable amounts will be available to utilise those tax losses against.

e. Going concern

The financial report has been prepared on a going concern basis, which assumes continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business for a period of at least twelve months from the date this financial report is approved.

For the financial year ended 31 December 2021, the Group incurred a loss of $9,349,639 and had net cash outflows from operations of $8,264,354. As at 31 December 2021, the Group had net current asset and net asset positions of $8,691,761 and $10,766,495 respectively.

The Group continues the commercialisation of its product range through distribution/ royalty agreements with its partners. Alongside this, the Group directly commercialises its product range by marketing its products and investing in sales capability and infrastructure as well as developing further products. The Group's commercialisation strategy means that the Group will continue to use its cash reserves and in order to continue to execute its strategy the Group announced on 23 February 2022 that it was undertaking a capital raising by way of placement and a share purchase plan.

After considering the above, the Directors have concluded that the Group will be able to fulfil all obligations as and when they fall due for the foreseeable future, being at least twelve months from the date of signing this financial report.

3. Significant Accounting Policies

The Group has consistently applied the following accounting policies to all periods in these financial statements.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

a. Parent entity information

In accordance with the *Corporations Act 2001*, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 24.

b. Basis of consolidation

i. Business combinations

The Group accounts for business combinations using the acquisition method when control is transferred to the Group, unless it is a combination involving entities or businesses under common control. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognised in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities.

Common control transactions record assets and liabilities acquired at their book value at the date of acquisition, rather than their fair value. The difference between the fair value of the consideration given and the carrying value of the assets and liabilities acquired is recognised as a common control reserve.

The consideration transferred does not include amounts related to the settlement of pre existing relationships. Such amounts are generally recognised in profit or loss.

ii. Subsidiaries

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

iii. Loss of control

When the Group loses control over a subsidiary, it derecognises the assets and liabilities of the subsidiary, and any related non controlling interest and other components of equity. Any resulting gain or loss is recognised in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost.

iv. Transactions eliminated on consolidation

Intra group balances and transactions, and any unrealised income and expenses arising from intra group transactions, are eliminated. Unrealised gains arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Group's interest in the investee. Unrealised losses are eliminated in the same way as unrealised gains, but only to the extent that there is no evidence of impairment.

c. Foreign currency

i. Foreign currency transactions

Transactions in foreign currencies are translated to the functional currency of the Group at exchange rates at the dates of the transactions.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined.

c. Foreign currency (cont.)

i. Foreign currency transactions (cont.)

Non monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Foreign currency differences are generally recognised in profit or loss and presented within finance costs.

ii. Foreign currency operations

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into the presentation currency at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into the functional currency at the average exchange rates for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transaction are used.

Foreign currency differences are recognised in equity and accumulated in the translation reserve.

d. Revenue from contracts with customers

Revenue from contracts with customers is recognised when a customer obtains control of the goods or services and when performance obligations have been satisfied assessing the following criteria:

i. Identification of distinct elements and separate performance obligations

In the case where the customer contract includes a sublicense and transfer of goods, the assessment must be made as to whether a separate performance obligation exists for each element. For current contracts held, whilst a license to specific IP has been given related to the Group's product, this only includes rights to distribute, not to use the IP to manufacture the product. Therefore, the licence transferred is not deemed to be a distinct element of the contract and only one performance obligation exists to transfer product to the distributor.

ii. Transfer of goods

Title and control pass to some of Next Science's customers at the point when the Group fulfils its obligation to deliver, and goods are available at the customer's premises. For these customers, the performance obligation (including the license) transfers at the point in time when each good is delivered. Therefore, revenue is recognised at the point in time when the product is delivered. For other customers, title and control pass when the product is delivered to the courier, with revenue being recognised at this point in time.

iii. Measurement of transaction price

Consideration of the contract can comprise a fixed element (upfront payment plus minimum annual purchase amounts) and variable elements (milestone payments).

Under AASB 15 the variable consideration is only included in the transaction price if it is 'highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur'.

In the case where milestone payments are received upon signing the contract and are not subject to regulatory approval, these amounts will be initially recognised as contract liabilities to be recognised over the life of the contract once product sales have commenced. However, where the milestone payments are subject to regulatory approval, for the variable consideration to be deemed 'most likely', this will only be included once regulatory approval has been received and recognised over the remaining life of the contract.

iv. Change in estimate

On 23rd November 2020, Next Science announced to the ASX that the distribution agreement with 3M for BLASTX®, would not be renewed at the end of 2021 and that BLASTX® would be transitioned back to Next Science in the first half of 2021.

As a result of the non renewal of the 3M contract, a change has been made to the time frame for recognition of the performance obligation in relation to the milestone payments received from 3M. The milestone payments would previously have been recognised as revenue over the period until the end of the 3M contract on 31 December 2021. The milestone payments have now been recognised as revenue over a shorter time period ending 1H 2021, as the transition of BLASTX® back to Next Science was completed during 1H 2021.

e. Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, it is recognised as income in equal amounts over the expected useful life of the related asset.

f. Finance income and finance costs

Finance income comprises interest income, dividend income and foreign currency gains. Interest income is recognised in profit or loss as it accrues using the effective interest method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instruments to the gross carrying amount of the financial asset or the amortised cost of the financial asset.

In calculating income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit impaired) or to the amortised cost of the liability. However, for financial assets that have become credit impaired subsequent to initial recognition interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit impaired, then the calculation of interest income reverts to the gross basis.

Finance costs comprise interest expense on borrowings, lease liabilities and converting notes, foreign currency losses and impairment losses recognised on financial assets. Foreign exchange gains and losses on intercompany assets and liabilities that are not eliminated upon consolidation are recognised in OCI. Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognised in profit or loss using the effective interest method.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

f. Finance income and finance costs (cont.)

Interest expenses includes interest in relation to lease liabilities and is calculated based on the bank borrowing rate as appropriate for the lease contract, with a range of 5.4% to 5.5% on current leases held.

Foreign currency gains and losses are reported on a net basis as either finance income or finance cost depending on whether foreign currency movements are in a net gain or net loss position.

g. Income tax

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in OCI.

The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received.

i. Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any tax liability arising from dividends.

Current tax assets and liabilities are offset only if certain criteria are met.

ii. Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognised for temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss, or on taxable temporary differences arising on the initial recognition of goodwill.

Deferred tax assets are recognised for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilised. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Unrecognised deferred tax assets are reassessed at each reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be used.

Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date.

The measurement of deferred tax reflects the tax consequences that could follow the manner in which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset only if certain criteria are met.

h. Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non current.

A liability is classified as current when: it is either expected to be settled in the Group's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non current.

Deferred tax assets and liabilities are always classified as non current.

i. Cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. For the statement of cash flows presentation purposes, cash and cash equivalents also includes bank overdrafts, which are shown within borrowings in current liabilities on the statement of financial position.

j. Trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement between 30 and 60 days.

The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

k. Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on the first in, first out principle.

l. Property, plant and equipment

i. Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. If significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

i. Recognition and measurement (cont.)

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to to the consolidated entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Any revaluation surplus reserve relating to the item disposed of is transferred directly to retained profits.

ii. Subsequent expenditure

Subsequent expenditure is capitalised only when it is probable that the future economic benefits associated with the expenditure will flow to the Group.

iii. Depreciation

Depreciation is calculated based on the cost of property, plant and equipment less their estimated residual values using the straight line basis over their estimated useful lives, and is generally recognised in profit or loss. Right of use assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Group will obtain ownership by the end of the lease term. Land is not depreciated.

The estimated useful lives of property, plant and equipment are as follows:

FIXED ASSET CLASS	USEFUL LIFE
Leasehold improvements	5-15 years
Plant and equipment	5 years
Furniture and fittings	5 years

Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

m. Right-of-use assets

A right of use asset is recognised at the commencement date of a lease. The right of use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right of use assets are depreciated on a straight line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Group has elected not to recognise a right of use asset and corresponding lease liability for short term leases with terms of 12 months or less and leases of low value assets. Lease payments on these assets are expensed to profit or loss as incurred.

n. Intangibles

i. Recognition and measurement

Research and development expenditure

Expenditure on research activities is recognised in profit or loss as incurred.

Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. Otherwise it is recognised in profit or loss as incurred. Subsequent to initial recognition, development expenditure is measured at cost less accumulated amortisation and any accumulated impairment losses.

Patents

Expenditure is capitalised in relation to patent application costs and amortised over the remaining life of the base patent as relevant. Costs will be no longer capitalised in the event that a patent application is no longer being pursued with any existing capitalised costs being impaired as an expense in the profit or loss.

Computer software

Computer software comprises computer application system software and licenses. Costs incurred in developing products or systems and costs incurred in acquiring software and licenses that will contribute to future period financial benefits through revenue generation and/or cost reduction are capitalised to computer software. Costs capitalised include external direct costs of materials and services, direct payroll and payroll related costs.

ii. Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognised in profit or loss as incurred.

iii. Amortisation

Amortisation is calculated based on the cost of intangible assets less their estimated residual values using the straight line method over their estimated useful lives, and is generally recognised in profit or loss.

The estimated useful lives of intangible assets are as follows:

Development Expenditure	8 years
Computer Software	2-3years
Patents	8-15 years

Amortisation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

Intangible assets, other than goodwill, have finite useful lives.

o. Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

p. Contract liabilities

Contract liabilities represent the consolidated entity's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the Group recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Group has transferred the goods or services to the customer.

q. Leases

i. Definition of a new lease

The determination of whether a contract contains a lease is on the basis of whether the customer has the right to control the use of an identified asset for a period of time in exchange for consideration. The Group has applied this definition to all lease contracts currently held.

ii. Lessee accounting

For all contracts determined to constitute a lease, right of use assets and lease liabilities are recognised in the consolidated statement of financial position, initially measured at the present value of future lease payments. When measuring these lease liabilities, the Group discounted lease payments using the interest rate implicit in the lease contract.

Right of use assets are tested for impairment in accordance with AASB 136 Impairment of assets. Lease incentives, if relevant, are recognised as part of the measurement of the right of use assets and lease liabilities. Depreciation is expensed on right of use assets and interest on lease liabilities, both recognised in the consolidated statement of profit or loss.

For presentation purposes, the total amount of cash paid in relation to leases is separated into a principal portion (presented within financial activities) and interest on lease liabilities, both recognised in the consolidated statement of profit or loss.

For short term leases (lease term of 12 months or less) and leases of low value assets, the Group has opted to recognise a lease expense on a straight line basis. This expense is presented within other expenses in the consolidated statement of profit or loss.

r. Provisions

A provision is recognised if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably and if it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as a finance cost.

s. Employee benefits

i. Short-term employee benefits

Short term employee benefits are benefits (other than termination benefits) that are expected to be settled within 12 months of the end of the financial year in which employees render the related service. Short term employee benefits include salaries and wages plus related on costs such as payroll tax, superannuation and workers compensation insurance and are

measured at the undiscounted amounts expected to be paid when the obligation is settled.

ii. Long-term employee benefits

Long term employee benefits include employees' long service leave and annual leave entitlements not expected to be settled within 12 months of the end of the financial year in which employees render the related service. Other long term employee benefits are measured at the present value of the expected future payments to be made to employees. Expected future payments incorporate anticipated future wage and salary levels, duration of service and employee departures and are discounted at rates determined by reference to market yields at the end of the reporting period on corporate bonds that have maturity dates that approximate the terms of the obligations. Any remeasurements for changes in assumptions of obligations for long term employee benefits are recognised in profit or loss in the periods in which the changes occur.

iii. Defined contribution plans

A defined contribution plan is a post employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. Obligations for contributions to employees' defined contribution plans are recognised as an expense as the related service is provided. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in future payments is available.

iv. Share-based payment arrangements

The fair value of performance rights and options granted is recognised as an employee expense with a corresponding increase in equity, on a straight line monthly basis over the vesting period in which the performance and/or service conditions are fulfilled after which the employee becomes unconditionally entitled to them. The cumulative expense recognised for share based payments at each reporting date until the vesting date reflects the extent to which the vesting period has ended and the Group's best estimate of the number of equity instruments that will ultimately vest. The expense or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of the period. No expense is recognised for awards that do not ultimately vest, except for equity settled transactions for which vesting are conditional upon a market or non vesting condition. These are treated as vesting irrespective of whether or not the market or non vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

t. Financial instruments

i. Recognition and initial measurement

The Group initially recognises trade receivables issued on the date that they are originated. All other financial assets and financial liabilities are recognised initially on the trade date.

ii. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as measured at amortised cost or fair value through profit or loss ("FVTPL").

Financial assets at amortised cost are subsequently measured at amortised cost using the effective interest method.

i. Classification and subsequent measurement (cont.)

Financial assets (cont.)

The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Financial assets at FVTPL are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

Financial liabilities

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held for trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

iii. Derecognition

Financial assets

The Group derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in transferred financial assets that is created or retained by the Group is recognised as a separate asset or liability.

Financial liabilities

The Group derecognises a financial liability when its contractual obligations are discharged or cancelled, or expired.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

u. Impairment

The Group recognises loss allowances for expected credit losses ("ECL") on financial assets and contract assets. Loss allowances where relevant are measured at an amount equal to a 12 month ECL.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECL's, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Group's historical experience and informed credit assessment and including forward looking information.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 90 days past due.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

The Group considers a financial asset to be in default when the borrower is unlikely to pay its obligations to the Group in full or the financial asset is more than 130 days past due.

ECLs are a probability weighted estimate of credit losses and are measured as the present value of all cash shortfalls discounted at the effective interest rate. Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount.

An impairment loss in respect of a financial asset measured at amortised cost is calculated as the difference between its carrying amount and the present value of the estimated future cash flows discounted at the asset's original effective interest rate. Losses are recognised in profit or loss and reflected in an allowance account against loans and receivables. Interest on the impaired asset continues to be recognised. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss.

v. Share capital

Ordinary shares

Incremental costs directly attributable to the issue of ordinary shares, net of any tax effects, are recognised as a deduction from equity.

w. Fair value measurement

'Fair value' is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Group has access at that date. The fair value of a liability reflects its non performance risk.

A number of the Group's accounting policies and disclosures require the measurement of fair values, for both financial and non financial assets and liabilities. When one is available, the Group measures the fair value using the quoted price in an active market. A market is regarded as 'active' if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no quoted price in an active market, then the Group uses valuation techniques that maximise the use of relevant observable inputs and minimise the use of unobservable inputs.

The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction.

x. Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM"). The CODM is responsible for allocating resources and assessing performance of the operating segments.

y. Earnings per share

i. Basic earnings per share

Basic earnings per share is calculated by dividing the profit or loss attributable to the owners of the Company excluding any costs of servicing equity other than ordinary shares, by the weighted average' number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

ii. Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

z. Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

4. Standards issued but not yet effective

A number of new standards are effective for annual periods beginning after 1 January 2022 and earlier application is permitted; however, the Group has not early adopted the new or amended standards in preparing these consolidated financial statements.

The Group plans to apply the amendments when they become effective and they are not expected to have a significant impact on the Group's consolidated financial statements:

i. Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to AASB 2014 10)

ii. Annual Improvements 2018 2020 Cycle (Amendments to AASB 1, 3, 9, 116, 137, 141) (Amendments to AASB 2020 3)

iii. AASB 2021 3 Amendments to Australian Accounting Standards - Covid 19 - Related Rent Concessions beyond 30 June 2021

5. Revenue and Other Income

	2021	2020
In USD	$	$
Revenue from contracts with customers	**8,947,591**	3,440,975

Identification of reporting operating segments

The Group operates in one segment, based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers (CODM)) in assessing performance and in determining the allocation of resources.

	REVENUE FROM CONTRACTS WITH CUSTOMERS		GEOGRAPHICAL NON-CURRENT ASSETS	
	2021	2020	2021	2020
In USD	$	$	$	$
United States of America	**8,854,153**	3,353,331	**1,205,596**	1,486,004
Australia	**93,438**	87,644	**2,279,570**	1,900,986
	8,947,591	3,440,975	**3,485,166**	3,386,990

Major customers

Revenues from two major customers of the Group represented 78% (2020: 91%) of the Group's total revenue.

OTHER INCOME

	2021	2020
In USD	$	$
Government assistance – COVID-19	**130,656**	318,077
Other income	**16,456**	38,497
	147,112	356,574

Income received in relation to grants will only be recognised when there is reasonable assurance when all conditions attaching to the grant have been complied with.

6. Individually Significant Items

The loss from ordinary activities before income tax includes the following expenses:

	2021	2020
In USD	$	$
Included in selling and distribution expenses *Depreciation and amortisation*	**23,811**	22,735
Included in research and development expenses *Depreciation and amortisation*	**567,984**	480,139
Included in administrative expenses *Depreciation and amortisation*	**198,477**	198,726

7. Other Expenses

	2021	2020
In USD	$	$
Loss on sale of fixed asset	**8,057**	2,796
Impairment loss on intangibles	**7,576**	7,605
Impairment loss on property, plant and equipment	**–**	2,951
	15,633	13,352

8. Employee Expenses

	2021	2020
In USD	$	$
Salaries and wages	**7,338,288**	7,034,911
Contributions to defined contribution funds	**43,564**	41,157
Share-based payments	**113,620**	482,973
	7,495,472	7,559,041

9. Finance Income

	2021	2020
In USD	$	$
Interest income	**16,515**	105,983
Interest income (loan to shareholder)	**–**	1,266
Net foreign exchange gain	**126,385**	190,005
	142,900	297,254

10. Finance Costs

	2021	2020
In USD	$	$
Interest expense on lease liabilities	**16,476**	21,179
	16,476	21,179

11. Income Tax Expense

Income tax expense comprises current and deferred tax expense and is recognised in profit or loss, except to the extent that it relates to a business combination or items recognised directly in equity or other comprehensive income. The components of tax expense comprise:

	2021	2020
In USD	$	$
Current tax	**–**	–
Deferred tax	**–**	–
	–	–
Reconciliation of income tax to accounting profit:		
Loss before income tax	**(9,349,639)**	(11,912,004)
Prima facie tax benefit on profit from ordinary activities before income tax at 26% (2020: 27.5%)	**(2,430,906)**	(3,275,801)
Tax effect of:		
Permanent differences	**(23,777)**	242,329
Effect of tax rate in foreign jurisdictions	**(319,306)**	(251,448)
Tax losses not brought to account	**2,968,169**	3,284,920
Prior period over/(under) provision	**(194,180)**	–
Total income tax expense	**–**	–

The unused tax losses as at 31 December were as follows:

	2021	2020
	$	$
Australia unused tax losses (in AUD)	**43,126,968**	30,652,663
USD unused tax losses (in USD)	**27,889,973**	21,503,856

Tax losses are recognised only to the extent that it is probable that the future taxable profit will be available against which the benefits can be utilised. Management has considered all the facts and circumstances and believe there is no material uncertainty over the availability of the tax losses.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

11. Income Tax Expense (cont.)

Australian entities

Movement in deferred tax assets and liabilities using the Company's domestic Australian tax rate of 26%

	OPENING BALANCE	RECOGNISED IN PROFIT OR LOSS	CLOSING BALANCE
In USD	$	$	$
2021 cost			
Intangibles	**(520,105)**	**(34,938)**	**(555,043)**
Employee benefits	**23,803**	**6,492**	**30,295**
Accrued expenses	**9,255**	**35,756**	**45,011**
Deferred revenue	**903,118**	**(545,745)**	**357,373**
Unused tax losses carried forward	**6,149,970**	**1,011,263**	**7,161,233**
Other items	**(39,484)**	**(8,002)**	**(47,486)**
Deferred tax assets not recognised	**(6,526,557)**	**(464,826)**	**(6,991,383)**
Deferred tax assets/(liabilities)	**–**	**–**	**–**
2020 cost			
Intangibles	(459,833)	(60,272)	(520,105)
Employee benefits	15,890	7,913	23,803
Accrued expenses	18,512	(9,257)	9,255
Deferred revenue	468,577	434,541	903,118
Unused tax losses carried forward	4,619,568	1,530,402	6,149,970
Other items	(28,185)	(11,299)	(39,484)
Deferred tax assets not recognised	(4,634,529)	(1,892,028)	(6,526,557)
Deferred tax assets/(liabilities)	–	–	–

11. Income Tax Expense (cont.)

US entities

Movement in deferred tax assets and liabilities using the US tax rate of 21%

	OPENING BALANCE	RECOGNISED IN PROFIT OR LOSS	CLOSING BALANCE
In USD	$	$	$
2021 cost			
Intangibles	**(117,566)**	**34,046**	**(83,520)**
Employee benefits	**1,075**	**1,106**	**2,181**
Accrued expenses	**104,118**	**(20,836)**	**83,282**
Unused tax losses carried forward	**5,698,521**	**158,373**	**5,856,894**
Other items	**(40,289)**	**874**	**(39,415)**
Deferred tax assets not recognised	**(5,645,859)**	**(173,563)**	**(5,819,422)**
Deferred tax assets/(liabilities)	**–**	**–**	**–**
2020 cost			
Intangibles	(130,439)	12,873	(117,566)
Employee benefits	4,097	(3,022)	1,075
Accrued expenses	77,307	26,811	104,118
Unused tax losses carried forward	4,673,389	1,025,132	5,698,521
Other items	(8,892)	(31,397)	(40,289)
Deferred tax assets not recognised	(4,615,462)	(1,030,397)	(5,645,859)
Deferred tax assets/(liabilities)	–	–	–

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

12. Cash and Cash Equivalents

	2021	2020
In USD	$	$
Cash at bank	**7,000,869**	8,100,416
	7,000,869	8,100,416

Reconciliation of cash flows from operating activities

	2021	2020
In USD	$	$
Loss for the year	**(9,349,639)**	(11,912,004)
Adjustments for:		
Depreciation and amortisation	**790,272**	701,600
Interest income (Note 9)	**–**	(1,266)
Share based payments (Note 8)	**113,620**	482,973
Unrealised foreign currency translation (gain)/loss	**(101,651)**	(72,143)
Directors fees paid as shares (Note 23)	**–**	30,520
Interest expense on right-of-use assets (Note 18)	**16,476**	21,179
Loss on sale of fixed asset (Note 16)	**8,057**	2,796
Impairment of intangible assets (Note 17)	**7,576**	7,606
Impairment of property, plant and equipment (Note 16)	**–**	2,951
Operating loss before changes in working capital and provisions	**(8,515,289)**	(10,735,788)
Change in operating assets and liabilities		
Change in trade and other receivables	**2,498,905**	(2,097,048)
Change in inventories	**(389,361)**	(629,516)
Change in other current assets	**(56,049)**	28,300
Change in trade and other payables	**109,884**	(28,011)
Change in employee benefits	**(2,891)**	(24,730)
Change in contract liabilities	**(1,909,553)**	1,580,149
	250,935	(1,170,856)
Net cash from operating activities	**(8,264,354)**	(11,906,644)

13. Trade and Other Receivables

In USD	2021 $	2020 $
Current		
Trade receivables	**865,831**	3,338,383
Loan to shareholders	**21,380**	49,662
	887,211	3,388,045
Non-Current		
Security deposit	**36,656**	36,656
	36,656	36,656

The carrying value of receivables is considered a reasonable approximation of fair value due to the short term nature of the balances. The Group has assessed any potential credit risk associated with these counterparties and deemed expected credit loss to be insignificant.

Information about the Group's exposure to credit and market risks, and impairment losses for trade receivables is included in Note 32 (c).

14. Inventories

In USD	2021 $	2020 $
Finished goods - at cost	**987,457**	631,644
Raw materials - at cost	**573,472**	539,923
	1,560,929	1,171,567
Less: provision for obsolete stock	**(60,407)**	(99,588)
	1,500,522	1,071,979

15. Other Current Assets

In USD	2021 $	2020 $
Current		
Prepayments and other assets	**476,049**	452,458
Term deposits	**367,129**	7,238,986
	843,178	7,691,444

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

16. Property, Plant and Equipment

In USD	2021 $	2020 $
Plant and equipment		
At cost	**1,158,763**	1,120,117
Accumulated depreciation	**(680,804)**	(572,261)
Total plant and equipment	**477,959**	547,856
Furniture, fixtures and fittings		
At cost	**250,905**	236,866
Accumulated depreciation	**(170,445)**	(135,140)
Total furniture, fixtures and fittings	**80,460**	101,726
Leasehold Improvements		
At cost	**199,754**	201,121
Accumulated amortisation	**(74,611)**	(62,570)
Total leasehold improvements	**125,143**	138,551
Total property, plant and equipment	**683,562**	788,133

Reconciliations of the written down values at the beginning and end of the current financial year and previous financial period are set out below.

In USD	PLANT AND EQUIPMENT $	FURNITURE AND FITTINGS $	LEASEHOLD IMPROVEMENTS $	TOTAL $
Balance at 1 January 2021	**547,856**	**101,726**	**138,551**	**788,133**
Additions	**123,112**	**17,380**	**–**	**140,492**
Disposals	**(7,847)**	**(210)**	**–**	**(8,057)**
Depreciation expense	**(185,164)**	**(38,436)**	**(13,411)**	**(237,011)**
Foreign exchange movements	**2**	**–**	**3**	**5**
Balance at the end of the year	**477,959**	**80,460**	**125,143**	**683,562**
Balance at 1 January 2020	542,251	111,422	158,914	812,587
Additions	174,056	39,188	–	213,244
Disposals	(1,144)	(1,652)	–	(2,796)
Depreciation expense	(167,307)	(44,281)	(20,381)	(231,969)
Impairment loss	–	(2,951)	–	(2,951)
Foreign exchange movements	–	–	18	18
Balance at the end of the year	547,856	101,726	138,551	788,133

17. Intangible Assets

	2021	2020
In USD	$	$
Patents and trademarks		
Cost	**1,507,814**	1,288,497
Accumulated amortisation	**(461,218)**	(326,387)
Net book value	**1,046,596**	962,110
Research and development expenditure		
Cost	**1,972,054**	1,623,330
Accumulated amortisation	**(486,796)**	(252,141)
Net book value	**1,485,258**	1,371,189
Computer software		
Cost	**121,701**	125,646
Accumulated amortisation	**(121,064)**	(124,009)
Net book value	**637**	1,637
Total Intangibles	**2,532,491**	2,334,936

	PATENTS AND TRADEMARKS	RESEARCH AND DEVELOPMENT	COMPUTER SOFTWARE	TOTAL
In USD	$	$	$	$
Balance at 1 January 2021	**962,110**	**1,371,189**	**1,637**	**2,334,936**
Additions	**219,317**	**356,949**	**–**	**576,266**
Impairment loss	**–**	**(7,576)**	**–**	**(7,576)**
Amortisation expense	**(134,831)**	**(235,304)**	**(1,000)**	**(371,135)**
Foreign exchange movements	**–**	**–**	**–**	**–**
Closing value at 31 December 2021	**1,046,596**	**1,485,258**	**637**	**2,532,491**
Balance at 1 January 2020	847,621	1,287,864	28,860	2,164,345
Additions	219,477	254,078	–	473,555
Impairment loss	(7,605)	–	–	(7,605)
Amortisation expense	(97,383)	(170,753)	(26,379)	(294,515)
Foreign exchange movements	–	–	(844)	(844)
Closing value at 31 December 2020	962,110	1,371,189	1,637	2,334,936

18. Right-of-use Assets

The Group holds leases for properties with lease terms ranging from 3 to 4.6 years.

	2021	2020
In USD	$	$
Property – right-of-use asset	**668,314**	587,668
Accumulated depreciation	**(435,858)**	(360,403)
	232,456	227,265
Amounts recognised in profit or loss		
Depreciation expensed	**182,127**	175,116
Interest expense	**16,476**	21,179
Expense relating to variable lease payments not included in the measurement of the lease liability	**89,146**	89,390
	287,749	285,685

The total cash outflow in relation to lease payments amounted to USD $212,759 (2020: USD $222,609).

Movement

	PROPERTY
In USD	$
Balance at 1 January 2021	**227,265**
Additions	**186,161**
Depreciation expense	**(182,127)**
Foreign exchange movements	**1,157**
Closing value at 31 December 2021	**232,456**
Balance at 1 January 2020	402,291
Depreciation expense	(175,116)
Foreign exchange movements	90
Closing value at 31 December 2020	**227,265**

19. Trade and Other Payables

	2021	2020
In USD	$	$
Current		
Trade payables	**515,579**	571,460
Other payables and accrued expenses	**657,417**	492,905
	1,172,996	1,064,365

All amounts are short-term and the carrying values are considered to be a reasonable approximation of fair value.

20. Contract Liabilities

	2021	2020
In USD	$	$
Current		
Contract liabilities	**91,177**	1,909,554
Non-Current		
Contract liabilities	**1,283,334**	1,374,510

Contract liabilities relate to consideration received in advance from customers for which revenue will be recognised as and when products are delivered or other performance obligations met.

21. Lease Liabilities

	2021	2020
In USD	$	$
Current		
Lease liabilities	**166,235**	170,946
Non-Current		
Lease liabilities	**109,802**	115,889
	276,037	286,835
Maturity analysis		
Not later than 1 year	**166,235**	170,946
Later than 1 year but not later than 5 years	**109,802**	115,889
Later than 5 years	**–**	–
	276,037	286,835

22. Employee Benefits

	2021	2020
In USD	$	$
Current		
Liability for annual leave	**109,611**	81,231
Non-Current		
Liability for long service leave	**17,295**	9,385

23. Capital and Reserves

a. Share capital

	FULLY PAID	PARTLY PAID	TOTAL
In number of shares			
Balance as at 1 January 2020	180,060,358	650,000	180,710,358
Shares issued in March 2020 (on conversion of employee share options) (i)	162,500	–	162,500
Partly paid shares converted into fully paid shares in April 2020	650,000	(650,000)	–
Shares issued in May 2020 in lieu of Non-Executive Director fees (ii)	23,820	–	23,820
Shares issued in July 2020 (on conversion of employee share options) (iii)	325,000	–	325,000
Shares issued in July 2020 (on conversion of employee share options) (iv)	325,000	–	325,000
Placement in September 2020 (v)	6,666,666	–	6,666,666
Share purchase plan in October 2020 (vi)	4,236,898	–	4,236,898
Shares issued in October 2020 (on conversion of employee share options) (vii)	84,500	–	84,500
Placement in November 2020 (viii)	1,666,667	–	1,666,667
Balance as at 31 December 2020	**194,201,409**	**–**	**194,201,409**
Shares issued in March 2021 on conversion of employee share options (ix)	**84,500**	**–**	**84,500**
Shares issued in April 2021 on conversion of employee share options (x)	**3,250,000**	**–**	**3,250,000**
Shares issued in May 2021 on conversion of employee share options (xi)	**438,000**	**–**	**438,000**
Balance as at 31 December 2021	**197,973,909**	**–**	**197,973,909**

23. Capital and Reserves (cont.)

	FULLY PAID	PARTLY PAID	TOTAL
In USD	$	$	$
Balance at 1 January 2020	90,493,591	199,999	90,693,590
Shares issued in March 2020 (on conversion of employee share options) (i)	50,377	–	50,377
Partly paid shares converted into fully paid shares in April 2020	199,999	(199,999)	–
Shares issued in May 2020 in lieu of Non-Executive Director fees (ii)	30,520	–	30,520
Shares issued in July 2020 (on conversion of employee share options) (iii)	100,750	–	100,750
Shares issued in July 2020 (on conversion of employee share options) (iv)	136,500	–	136,500
Placement in September 2020 (v)	5,627,879	–	5,627,879
Share purchase plan in October 2020 (vi)	3,550,085	–	3,550,085
Shares issued in October 2020 (on conversion of employee share options) (vii)	26,195	–	26,195
Placement in November 2020 (viii)	1,453,310	–	1,453,310
Capital raising costs	(387,739)	–	(387,739)
Balance at 31 December 2020	**101,281,467**	**–**	**101,281,467**
Shares issued in March 2021 (on conversion of employee share options) (ix)	**35,490**	**–**	**35,490**
Shares issued in April 2021 (on conversion of employee share options) (x)	**1,365,000**	**–**	**1,365,000**
Shares issued in May 2021 (on conversion of employee share options) (xi)	**245,280**	**–**	**245,280**
Capital raising costs	**(6,230)**	**–**	**(6,230)**
Balance at 31 December 2021	**102,921,007**	**–**	**102,921,007**

23. Capital and Reserves (cont.)

i. On 2 March 2020, 162,500 round 2 Equity Incentive Plan (ECP) employee share options converted to 162,500 ordinary shares at a price of AUD$0.47.

ii. On 6 May 2020, the following ordinary shares were issued in lieu of non-executive directors fees:

- 12,537 ordinary shares were issued at a price of AUD$1.99 to Daniel Spira
- 11,283 ordinary shares were issued at a price of AUD$1.99 to Aileen Stockburger

iii. On 2 July 2020, 325,000 round 2 Equity Incentive Plan (ECP) employee share options converted to 325,000 ordinary shares at a price of AUD$0.45.

iv. On 2 July 2020, 325,000 round 2 Equity Incentive Plan (ECP) employee share options converted to 325,000 ordinary shares at a price of AUD$0.61.

v. On 24 September 2020, Next Science raised A$7,999,999 via a Placement at A$1.20 per share.

vi. On 19 October 2020, Next Science raised A$4,999,663 via a Share Purchase Plan at A$1.18 per share.

vii. On 23 October 2020, 84,500 round 2 Equity Incentive Plan (ECP) employee share options converted to 84,500 ordinary shares at a price of AUD$0.44.

viii. On 19 November 2020, Next Science raised A$2,000,000 via a Placement at A$1.20, approved by shareholders at a general meeting held on 18 November 2020.

ix. On 18 March 2021, 84,500 round 3 Equity Incentive Plan (ECP) employee share options converted to 84,500 ordinary shares at a price of AUD$0.54.

x. (x) Between 13 April 2021 and 15 April 2021, 3,250,000 round 3 Equity Incentive Plan (ECP) employee share options converted to 3,250,000 ordinary shares at a price of AUD$0.55

xi. (xi) On 3 May 2021, 438,000 round 4 Equity Incentive Plan (ECP) employee share options converted to 438,000 ordinary shares at a price of AUD$0.72.

Ordinary shares

Fully paid ordinary shares

Ordinary shares participate in dividends and the proceeds on winding up of the Company in proportion to the number of shares held. At shareholders' meetings, each ordinary share is entitled to one vote when a poll is called.

Partly paid ordinary shares

The partly paid ordinary shares are called on in accordance with their underlying arrangements (due for payment April 2020) and as required by the Company. In any case, on winding up the company, the balance of partly paid shares, if any, may be called up. The proceeds on winding up are proportional to the amounts paid on partly paid shares. Partly paid shares carry equal dividend participation and voting rights as fully paid shares, although any dividends must be first be applied to the unpaid balance on the shares.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

23. Capital and Reserves (cont.)

b. Reserves

	2021	2020
In USD	$	$
Foreign currency translation reserve	**(1,349,143)**	(801,736)
Common control reserve	**(42,596,715)**	(42,596,715)
Share option reserve	**2,140,298**	2,125,541
Performance rights reserve	**96,250**	–
	(41,709,310)	(41,272,910)

Foreign currency translation reserve

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations where their functional currency is different to the Group's presentation currency.

Common control reserve

The acquisition of the share capital of Microbial Defense Systems Holdings Inc ("MDS") by the Company on 22 December 2017 was accounted for as a common control transaction. As a consequence, the difference between the fair value of the consideration paid ($43,862,500) and the existing book values of assets and liabilities of MDS ($1,265,785) were debited to a common control reserve, directly within equity.

Share option reserve

The share option reserve comprises the value of the share based payment arrangements recognised in equity.

c. Dividends

No dividends were paid or declared by the Company during the financial year.

d. Dividend franking account

The Company has franking credits available to shareholders of Nil.

e. Capital management

The Group's objectives when managing capital are to safeguard its ability to continue as a going concern so that it can continue to provide returns for shareholders and benefits for other stakeholders, maintain sufficient financial flexibility to pursue its growth objectives and maintain an optimal capital structure to reduce the cost of capital.

24. Parent Entity Information

As at, and throughout, the financial year to 31 December 2021 the parent entity of the Group was Next Science Limited.

Statement of profit or loss and other comprehensive income

	PARENT 2021	PARENT 2020
In USD	$	$
Loss after income tax	**(10,733,399)**	(6,081,965)
Other comprehensive income / (loss)	**(478,466)**	598,176
Total comprehensive loss	**(11,211,865)**	(5,483,789)

Statement of financial position

	PARENT 2021	PARENT 2020
In USD	$	$
Assets		
Total current assets	**4,033,709**	2,469,478
Total non-current assets	**13,308,038**	24,305,150
Total assets	**17,341,747**	26,774,628
Liabilities		
Total current liabilities	**(451,638)**	(423,201)
Total non-current liabilities	**–**	–
Total liabilities	**(451,638)**	(423,201)
Total net assets	**16,890,108**	26,351,427
Equity		
Share capital	**102,921,005**	101,281,467
Common control reserve	**(27,257,549)**	(27,257,549)
Foreign currency translation reserve	**(997,204)**	(518,738)
Share option reserve	**2,140,298**	2,125,541
Performance rights reserve	**96,250**	–
Accumulated losses	**(60,012,691)**	(49,279,294)
Total equity	**16,890,108**	26,351,427

24. Parent Entity Information (cont.)

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The parent entity had no guarantees as at 31 December 2021 and 31 December 2020.

Contingent liabilities

The parent entity had no contingent liabilities as at 31 December 2021 and 31 December 2020.

Capital commitments - Property, plant and equipment

The parent entity had no capital commitments for property, plant and equipment as at 31 December 2021 and 31 December 2020.

Significant accounting policies

The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 3, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.

25. Group Entities

Set out below is the Group structure listing all subsidiaries as at 31 December 2021.



26. Related Parties

a. Key management personnel compensation

Key management personnel ("KMP") are defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group, directly and indirectly, and include the Directors, executive and non executive, as well as certain other senior executives. The totals of remuneration of the KMP of the Company included within employee expenses are as follows:

	2021	2020
In USD	$	$
Short-term employee benefits	**1,849,829**	1,614,212
Other long-term employee benefits	**6,822**	5,023
Post-employment benefits	**42,371**	47,613
Share-based payment benefits	**113,620**	411,372
Total	**2,012,642**	2,078,220

Short-term employee benefits

Short-term employee benefits include fees and benefits paid to the executive directors and other KMP as well as salary, fringe benefits and cash bonuses awarded to the non-executive directors.

Post-employment benefits

Post-employment benefits are the cost of superannuation contributions made during the year.

b. Key management personnel transactions

KMPs of the Company hold 11.02% (2020: 13.9%) of the issued capital of the Company as at 31 December 2021.

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

27. Share-based Employee Incentive Arrangements

Equity Incentive Plan (equity settled)

Prior to listing on the ASX, the Group established an Equity Incentive Plan (ECP) and an Employee Share Option Plan (ESOP). The purpose of the Plans is to attract and retain the types of employees, consultants and directors who will contribute to the Company's long term success; provide incentives that align the interests of Employees, Consultants and Directors with those of the shareholders of the Company; and promote the success of the Company's business. As at 31 December 2021, there are 2,890,000 options over ordinary shares on issue (2020: 8,092,500 options), representing 1.46% (2020: 4.17%) of the Company's total share capital, granted to the employees and Directors of the Company.

The grant dates, vesting dates and exercise prices vary and are as follows:

GRANT DATE AND VESTING CONDITIONS (I)	EXPIRY DATE	NO OF OPTIONS AS AT 31 DEC 2020	GRANTED	EXERCISED (II)	LAPSED	NO OF OPTIONS AS AT 31 DEC 2021	VESTED AS AT 31 DEC 2021
16-Apr-18 (1)	16-Apr-21	734,500	–	(734,500)	–	–	–
16-Apr-18 (5)	16-Apr-21	2,340,000	–	(1,560,000)	(780,000)	–	–
16-Apr-18 (4)	16-Apr-21	1,040,000	–	(1,040,000)	–	–	–
16-Apr-18 (2)	16-Apr-22	78,000	–	–	–	78,000	78,000
17-Dec-18 (3)	17-Dec-23	2,470,000	–	–	(650,000)	1,820,000	1,820,000
17-Dec-18 (2)	17-Dec-23	1,430,000	–	(438,000)	–	992,000	992,000
Totals		**8,092,500**	–	**(3,772,500)**	**(1,430,000)**	**2,890,000**	**2,890,000**

i. Vesting conditions are as follows:

1. 1 year service from grant date
2. 2 years service from grant date
3. 3 years service from grant date
4. Immediately upon grant
5. Various, including financial and non-financial conditions; relating to Judith Mitchell's share options

27. Share-based Employee Incentive Arrangements (cont.)

ii. The weighted average share price for the options exercised during the year was USD $0.44 (2020: USD $0.35).

As at 31 December 2021, 2,890,000 options have vested (2020: 4,842,500).

The fair value has been measured using the Black Scholes formula. Service and non market performance conditions attached to the arrangements were not taken into account in measuring fair value.

The inputs used in the measurement of the fair values at grant date and measurement date were as follows:

	GRANT DATE		
	16-APR-18	17-DEC-18	19-FEB-19
FV at grant date (USD)	0.20-0.22	0.33	0.02
Share price at grant date (USD)	0.42	0.56	0.57
Exercise price (USD)	0.42	0.56	0.57
Expected volatility	91%		
Expected life	3-4 years		
Expected dividends	0%		
Risk free interest rate	2.25%-5.0%		

Expected volatility is measured based on peer companies and expected life is the number of days until expiry.

The fair value of the performance rights granted to Dustin Haines is deemed to represent the value of Dustin Haines's services received over the vesting period. These values were calculated applying the following inputs to performance rights issued:

	PERFORMANCE RIGHTS
Grant date	22-Feb-21
Weighted average fair value per performance right	USD $0.9248
Number of performance rights issued	340,602
Remaining life of the performance rights	3 years

28. Contingent Liabilities and Capital Commitments

In August 2021, Irrimax Corporation, a competitor of Next Science in the wound irrigation sector, filed a complaint and subsequently served on its complaint in the United States District Court for the Northern District of Georgia alleging common law unfair competition and false advertising regarding XPERIENCE™. Next Science denies the allegations and is vigorously defending the complaint.

The Group has no capital commitments as at 31 December 2021 (2020: nil).

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

29. Events Occurring After the Reporting Date

As detailed above, in January 2022, Next Science and Zimmer reached agreement in respect of a new US distribution agreement in relation to the supply of a white labelled version of XPERIENCE™ under Zimmer's own labelling (excluding the US plastic reconstructive surgery market which is covered by TELA Bio, Inc's distribution agreement detailed below), and Zimmer withdrew its District Court proceedings.

In conjunction with agreeing the new XPERIENCE™ distribution agreement, Next Science and Zimmer also agreed a refreshed distribution arrangement for Bactisure. The revised Bactisure arrangements include a revised agreement term. The agreement term will end on 31 December 2026 with Zimmer having the option to extend the agreement for an additional five year period by providing 6 months' prior notice.

The Group announced on 23 February 2022 that it was undertaking a capital raising by way of a placement and a share purchase plan.

There has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event, other than those matters detailed above, of a material and unusual nature likely, in the opinion of the directors of the Company, to affect significantly the operations of the Group, the results of those operations, or the state of affairs of the Group, in future financial years.

30. Auditors' Remuneration

	2021	2020
In USD	$	$
Audit and assurance related services KPMG Australia		
Audit of financial statements	**82,466**	80,372
Total audit and assurance services	**82,466**	80,372
Other services KPMG Australia		
Taxation services	**11,602**	2,432
Other services	**10,494**	19,230
Total other services	**22,096**	21,662
Total auditor's remuneration	**104,562**	102,034

31. Earnings Per Share

a. Reconciliation of earnings to profit or loss from continuing operations

	2021	2020
In USD	$	$
Loss after tax	**(9,349,639)**	(11,912,004)
Basic and diluted earnings per share (USD cents)	**(4.75)**	(6.36)
Weighted average number of shares	**196,882,812**	187,185,169

32. Financial Risk Management

a. Overview

The Group's activities expose it to various financial risks including: credit risk, liquidity risk and market risk.

This note presents information about the Group's exposure to each of these risks, its objectives, policies and processes for measuring and managing risk.

b. Risk management framework

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework with assistance from the Audit and Risk Committee (as detailed below). The Group's risk management framework has been established to identify and analyse the material risks faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to the risk appetite set by the Board. The Group's risk management framework is reviewed at least annually by the Audit and Risk Committee and the consideration of changes in the Group's risk profile and mitigating actions and controls is a standing item at Audit and Risk Committee meetings.

Audit and Risk Committee

The Audit and Risk Committee responsibilities in relation to risk management are to:

- oversee the establishment, and maintenance by management, of processes to ensure that there is an adequate and effective system to identify and manage material business risks;
- monitor the Group's Risk Register to confirm that key risks have been identified and adequate controls are in place to mitigate risks so far as reasonably practicable;
- receive reports from management on new and emerging sources of risk and the proposed risk controls to mitigate those risks;
- receive reports from management and the external auditor on any material incident involving fraud or a breakdown of the Group's risk controls and the lessons learned;
- review, at least annually, the Group's risk management framework to confirm that it continues to be sound and that the Group is operating with due regard to the risk appetite set by the Board;

14. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
For the Year Ended 31 December 2021

32. Financial Risk Management (cont.)

- monitor the need for, and if considered necessary, require, an internal or external audit of critical areas of risk;
- oversee the establishment of procedures for the receipt, handling and investigation of whistleblower disclosures;
- oversee the establishment of, and monitor, assurance mechanisms for monitoring:
  - the Group's culture and compliance with the Group's Values; and
  - compliance with the Group's corporate governance policies and procedures, contractual obligations and the laws applicable to the Group and its operations;
- oversee the Group's annual insurance program, having regard to the Group's business and the insurable risks within its business;
- assess the adequacy of controls, including disaster recovery and business continuity plans, for preserving and re establishing financial and operational information in the event of a disaster; and
- review and make recommendations to the Board in relation to public disclosures made by the Group regarding material business risks.

The Board considers the Group's risk management framework to be appropriate for the size and level of operations of the Group.

c. Credit risk

Cash and cash equivalents

The Group held cash and cash equivalents of USD $7,000,869 and USD $367,129 in term deposits at 31 December 2021 (2020: USD $8,100,416 in cash and USD $7,238,986 in term deposits). The cash and cash equivalents are held with credit worthy bank and financial counterparties. The expected credit loss of each of these banks and counterparties are considered to be extremely low; accordingly any expected credit losses are deemed to be insignificant.

Trade receivables and contract assets

Credit risk on trade receivables is the risk of financial loss if a customer fails to meet its c ontractual obligations.

The carrying amounts of financial assets represents the maximum credit exposure.

Maximum exposure to credit risk for trade receivables by type of counterparty was as follows:

	2021	2020
In USD	$	$
Distribution & Licensing Partners	**593,644**	3,295,464
Hospitals & Surgery Centres	**272,187**	42,919
Other	**–**	–
	865,831	3,338,383

As at 31 December 2021, Zimmer Surgical Inc (worldwide) accounted for over 67% of the trade receivables (2020: Zimmer Surgical Inc accounted for over 75% of the trade receivables).

32. Financial Risk Management (cont.)

c. Credit risk (cont.)

i. Risk management

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate. Details of concentration of revenue are included in Note 5.

The Audit and Risk Committee has established a credit policy under which each new customer is analysed individually for creditworthiness before the Group's standard payment and delivery terms and conditions are offered. The Group's review of new customers includes customer due diligence and credit agency information (Dun & Bradstreet Corporation), if available. Sale limits are established for each customer and reviewed periodically. Any sales exceeding those limits require approval according to an approval matrix.

The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements.

In monitoring customer credit risk, customers are grouped according to their credit characteristics, including whether they are an individual hospital or surgery centre or whether they are a distribution partner with which Next Science has a licensing or distribution agreement. Further consideration is given to their geographic location and trading history with the Group and existence of any previous financial difficulties.

ii. Impaired trade receivables

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indications of this include significant financial difficulties of the debtor, the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for an extensive period of time.

Impairment losses are recognised in the profit or loss statement within selling and distribution expenses. Subsequent recoveries of amounts previously written off are credited against selling and general expenses.

As at 31 December 2021, trade receivables with a nominal value of $Nil (2020: Nil) were considered impaired and fully provided for.

iii. Past due not impaired

As at 31 December 2021, trade receivables of $67,247 (2020: $105,505) were past due but not impaired. These relate to customers for whom there is no recent history of default.

32. Financial Risk Management (cont.)

The aging analysis of trade receivables is as follows:

	2021	2020
In USD	$	$
0 - 30 days	**781,855**	3,009,686
31 - 60 days	**62,302**	162,775
61 - 90 days	**21,006**	165,922
91 - 120 days	**668**	–
More than 120 days	**–**	–
Total	**865,831**	3,338,383

d. Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. The Group manages liquidity risk by monitoring net cash balances, actual and forecast operating cash flows.

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted and include estimated interest payments and exclude the impact of netting agreements.

	LESS THAN 6 MONTHS	6-12 MONTHS	BETWEEN 1 AND 5 YEARS	TOTAL CONTRACTED AMOUNTS
In USD	$	$	$	$
At 31 December 2021				
Trade and other payables	**1,172,996**	**–**	**–**	**1,172,996**
Lease liabilities	**91,540**	**74,695**	**109,802**	**276,037**
Total	**1,264,536**	**74,695**	**109,802**	**1,449,033**
At 31 December 2020				
Trade and other payables	1,064,365	–	–	1,064,365
Lease liabilities	74,762	96,183	115,889	286,834
Total	1,139,127	96,183	115,889	1,351,199

The cash flows in the maturity analysis are not expected to occur significantly earlier or be for a significantly different amount than contractually disclosed above.

32. Financial Risk Management (cont.)

e. Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates, will affect the Group's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

Interest rate risk

The Group is not exposed to any significant interest rate risk. There is minimal exposure to the impact of adverse changes in benchmark interest rates. The Group is exposed to variable interest rate risks at the reporting date on cash and short term deposits. A reasonably possible change of 100 basis points in interest rates at the reporting date would have increased or decreased profit after tax by $42,906 (2020: $122,864). This analysis assumes that all other variables, in particular foreign currency rates, remain constant.

Currency risk

Currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The source and nature of this risk arise from operations and translation risks. The Group's reporting currency is United States Dollars ("USD"). However, the international operations give rise to an exposure to changes in foreign exchange rates as amounts of expenditure are from Australia and denominated in currencies other than USD.

The carrying amounts of the Group's foreign currency denominated financial assets (trade and other receivables including accrued income) and financial liabilities (trade and other payables) at the reporting date were as follows:

	2021	2020
In USD	$	$
AUD financial assets converted to USD	**4,006,776**	7,282,214
AUD financial liabilities converted to USD	**(300,868)**	(137,932)
Net exposure in statement of financial position	**3,705,908**	7,144,282

A reasonably possible strengthening (weakening) of the Unites States Dollar against all other currencies at 31 December 2021 would have affected the measurement of financial instruments denominated in a foreign currency and affected profit or loss and equity by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

32. Financial Risk Management (cont.)

	% CHANGE	PROFIT BEFORE TAX STRENGTHEN	PROFIT BEFORE TAX WEAKEN	EQUITY STRENGTHEN	EQUITY WEAKEN
In USD	$	$	$	$	$
2021					
Australian Dollars	**10%**	**(370,591)**	**370,591**	**(370,591)**	**370,591**
2020					
Australian Dollars	10%	(714,428)	714,428	(714,428)	714,428

The percentage change is the expected overall volatility of the significant currencies, which is based on management's assessment of reasonable possible fluctuations taking into consideration movements over the last 12 months and the spot rate at each reporting date.

15. DIRECTORS' DECLARATION

1. In the opinion of the directors of Next Science Limited (the "Company"):
   a. The consolidated financial statements and notes that are set out on pages 41 to 88 and the Remuneration Report on pages 26 to 38 in the Directors' Report, are in accordance with the Corporations Act 2001, including:
      i. giving a true and fair view of the financial position of the Group as at 31 December 2021 and of its performance for the financial year ended on that date; and
      ii. complying with Australian Accounting Standards and the Corporations Regulations 2001; and
   b. there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.
3. The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the chief executive officer and chief financial officer for the financial year ended 31 December 2021.
3. The Directors draw attention to Note 2(a) to the consolidated financial statements, which includes a statement of compliance with International Financial Reporting Standards.

Signed in accordance with a resolution of directors:

Mark Compton, AM
Chair

Dated: 23rd February 2022

INDEPENDENT AUDITOR'S REPORT

#NextScienceHeals

Independent Auditor's Report

KPMG

To the shareholders of Next Science Limited

Report on the audit of the Financial Report

Opinion

We have audited the ***Financial Report*** of Next Science Limited (the Company).

In our opinion, the accompanying Financial Report of the Company is in accordance with the *Corporations Act 2001*, including:

- giving a true and fair view of the ***Group***'s financial position as at 31 December 2021 and of its financial performance for the year ended on that date; and
- complying with *Australian Accounting Standards* and the *Corporations Regulations 2001*.

The ***Financial Report*** comprises:

- Consolidated statement of financial position as at 31 December 2021
- Consolidated statement of profit or loss and other comprehensive income, Consolidated statement of changes in equity, and Consolidated statement of cash flows for the year then ended
- Notes including a summary of significant accounting policies
- Directors' Declaration.

The ***Group*** consists of the Company and the entities it controlled at the year-end or from time to time during the financial year.

Basis for opinion

We conducted our audit in accordance with *Australian Auditing Standards*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report.

We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the Financial Report in Australia. We have fulfilled our other ethical responsibilities in accordance with these requirements.

16. INDEPENDENT AUDITOR'S REPORT

KPMG

Key Audit Matters

Key Audit Matters are those matters that, in our professional judgement, were of most significance in our audit of the Financial Report of the current period.

This matter was addressed in the context of our audit of the Financial Report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.

Revenue recognition – USD 8,947,591

Refer to Note 5 to the Financial Report

The key audit matter	How the matter was addressed in our audit
We focused on revenue recognition as a key audit matter due to the significant audit effort required by us to test the Group's revenue given the: • Significance of revenue to the financial statements; • Varying terms and conditions within each customer contract such as product sales, advance deposits, true up payments and milestone payments. This increases the effort required by the audit team to evaluate the timing and measurement of revenue recognised by the Group, and associated contract liabilities; • Group has manual processes and controls which may increase the risk of error in recognition of revenue at the end of the reporting period due to differing terms of trade and extended delivery periods of customer contracts.	Our procedures included: • Evaluated the appropriateness of the Group's revenue recognition policies against the requirements of AASB 15 Revenue from Contracts with Customers. • For a sample of transactions, across customer contracts including product sales, advance deposits, true up payments and milestone payments, we: o checked the terms and conditions of the customer contract for consistency to the Group's policy for timing and measurement of revenue recognition; o checked the amount, nature and date of revenue recognition through evaluation of the terms and conditions in the underlying customer contract, date of completion of freight forwarding services from underlying freight documents such as the waybill, underlying sales invoices and bank statement cash receipts. • For the calculation of deferred revenue, we checked the remaining life of the contract in the calculation of deferred revenue to the underlying key customer contract. • Selected a sample of revenue transactions across differing terms of trade and extended delivery periods for the last two weeks of the reporting period and the first two weeks of the next reporting period. For each sample selected, we checked the amount and timing of revenue recorded by the Group to the underlying customer contracts, sales invoice and to freight documents. • Assessed the disclosures in the financial report using our understanding obtained from our testing and against the requirements of the accounting standards.

KPMG

Other Information

Other Information is financial and non-financial information in Next Science Limited's annual reporting which is provided in addition to the Financial Report and the Auditor's Report. The Directors are responsible for the Other Information.

The Other Information we obtained prior to the date of this Auditor's Report was the Directors' Report and Renumeration Report. The Our Purpose Page, Chairman's Letter, Managing Director's Report, Investor Information and Corporate Directory are expected to be made available to us after the date of the Auditor's Report.

Our opinion on the Financial Report does not cover the Other Information and, accordingly, we do not express an audit opinion or any form of assurance conclusion thereon, with the exception of the Renumeration Report and our related assurance opinion.

In connection with our audit of the Financial Report, our responsibility is to read the Other Information. In doing so, we consider whether the Other Information is materially inconsistent with the Financial Report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We are required to report if we conclude that there is a material misstatement of this Other Information, and based on the work we have performed on the Other Information that we obtained prior to the date of this Auditor's Report we have nothing to report.

Responsibilities of the Directors for the Financial Report

The Directors are responsible for:

- preparing the Financial Report that gives a true and fair view in accordance with *Australian Accounting Standards* and the *Corporations Act 2001*
- implementing necessary internal control to enable the preparation of a Financial Report that gives a true and fair view and is free from material misstatement, whether due to fraud or error
- assessing the Group and Company's ability to continue as a going concern and whether the use of the going concern basis of accounting is appropriate. This includes disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless they either intend to liquidate the Group and Company or to cease operations, or have no realistic alternative but to do so.

16. INDEPENDENT AUDITOR'S REPORT

KPMG

Auditor's responsibilities for the audit of the Financial Report

Our objective is:

- to obtain reasonable assurance about whether the Financial Report as a whole is free from material misstatement, whether due to fraud or error; and
- to issue an Auditor's Report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with *Australian Auditing Standards* will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error. They are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Financial Report.

A further description of our responsibilities for the audit of the Financial Report is located at the *Auditing and Assurance Standards Board* website at: https://www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf. This description forms part of our Auditor's Report.

Report on the Remuneration Report

Opinion

In our opinion, the Remuneration Report of Next Science Limited for the year ended 31 December 2021, complies with *Section 300A* of the *Corporations Act 2001*.

Directors' responsibilities

The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with *Section 300A* of the *Corporations Act 2001*.

Our responsibilities

We have audited the Remuneration Report included in pages 26 to 38 of the Directors' report for the year ended 31 December 2021.

Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with *Australian Auditing Standards*.

KPMG

KPMG

Tony Nimac
Partner

Sydney

23 February 2022

#NextScienceHeals

INVESTOR INFORMATION

Number of securityholders

At the specified date, there were 5,066 holders of ordinary shares (quoted and unquoted) and 7 holders of options (unquoted) over ordinary shares. These were the only classes of equity securities on issue.

Shareholding Distribution

SIZE OF SHAREHOLDING	NUMBER OF HOLDERS	NUMBER OF SHARES	% OF ISSUED CAPITAL
1-1,000	1,368	754,318	0.37
1,001 – 5,000	1,732	5,003,501	2.44
5,001 – 10,000	813	6,482,727	3.16
10,001 – 100,000	1,042	29,177,608	14.24
100,000 and above	111	163,413,956	79.78
Total	**5,066**	**204,832,110**	**100**

Twenty largest holders of quoted ordinary shares

NAME	SHARES HELD	% OF ISSUED CAPITAL
AUCKLAND TRUST COMPANY LTD	56,019,938	27.35
WALKER GROUP HOLDINGS PTY LIMITED	22,432,678	10.95
DR MATTHEW FRANCO MYNTTI	13,354,989	6.52
UBS NOMINEES PTY LTD	6,814,041	3.33
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 2	6,515,600	3.18
JUDITH MITCHELL	5,689,936	2.78
MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED	4,956,970	2.42
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	3,611,551	1.76
SANDHURST TRUSTEES LTD <ENDEAVOR ASSET MGMT MDA A/C>	3,388,128	1.65
J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	3,051,844	1.49
MR CHARLES ROBERT DIRCK WITTENOOM	3,000,000	1.46
NATIONAL NOMINEES LIMITED	2,211,020	1.08
CITICORP NOMINEES PTY LIMITED	2,070,238	1.01
BOND STREET CUSTODIANS LIMITED <LAM1 - D08047 A/C>	1,364,449	0.67
SCONE INVESTMENTS PTY LTD	1,159,452	0.57
BNP PARIBAS NOMINEES PTY LTD HUB24 CUSTODIAL SERV LTD <DRP A/C>	1,112,433	0.54
G & N LORD SUPERANNUATION PTY LTD <GNR SUPERANNUATION FUND A/C>	965,000	0.47
KA-TET PTY LTD <THE ROSENROT TRUST>	890,500	0.43
MRS DESIREE HANCOX DARROCH	887,500	0.43
BROOK ST SMSF PTY LTD <BROOK ST SMSF A/C>	835,702	0.41
Total	**140,331,969**	**68.51**

17. INVESTOR INFORMATION
As at 11 March 2022

Substantial holders

Substantial holders as disclosed in substantial holding notices given to the Company were as follows:

NAME OF SUBSTANTIAL HOLDER	NUMBER OF SHARES OVER WHICH RELEVANT INTEREST IS HELD	% OF ISSUED CAPITAL
Walker Group Holdings Pty Limited, Auckland Trust Company Limited as trustee of the Second Pacific Master Superannuation Fund and Langley Alexander Walker	76,072,938	39.53
Matthew Myntti	14,068,000	7.11

Securities subject to escrow

There were no quoted or unquoted securities subject to a restriction period or voluntary escrow period except for 1,560,000 fully paid ordinary shares held by the CEO and Managing Director, Judith Mitchell, which are subject to a 12 month voluntary holding lock expiring 15 April 2022.

Unquoted options over ordinary shares

There were 2,812,000 unquoted options over ordinary shares on issue:

UNQUOTED OPTIONS – DESCRIPTION	NUMBER OF OPTIONS	NUMBER OF HOLDERS
Options exercisable at US$0.56 per option expiring 17 December 2023	2,812,000	7

Optionholding distribution

SIZE OF OPTIONHOLDING	NUMBER OF HOLDERS	NUMBER OF OPTIONS	% OF ISSUED OPTIONS
1 – 1,000	0	0	0
1,001 – 5,000	0	0	0
5,001 – 10,000	0	0	0
10,001 – 100,000	1	82,000	2.92
100,000 and above	6	2,730,000	97.08
Total	**7**	**2,812,000**	**100**

The Company's Chief Operating Officer, Jon Swanson, is the only person who holds 20% or more of the unquoted options on issue. The options issued to Mr Swanson were issued under an employee incentive scheme.

17. INVESTOR INFORMATION

As at 11 March 2022

Voting rights

Ordinary shares (including partly paid shares) carry voting rights on a one for one basis and unlisted options do not carry voting rights.

Unmarketable parcels

There are no holders of an unmarketable parcel of shares based on the closing market price of $0.905 at the specified date.

18. CORPORATE DIRECTORY

31 December 2021

Independent Non-Executive Chair:	Mark Compton AM
CEO and Managing Director:	Judith Mitchell
Non-Executive Directors:	Bruce Hancox Daniel Spira Aileen Stockburger
Company Secretary	Gillian Nairn
Registered office	Suite 1902 Level 19, Tower A The Zenith Building 821 Pacific Highway Chatswood NSW 2067
Share register	Link Market Services Limited Level 12, 680 George Street Sydney NSW 2000
Auditor	KPMG Australia 300 Barangaroo Avenue Sydney NSW 2000
Solicitors	HWL Ebsworth Lawyers Level 14, Australia Square 264-278 George Street Sydney NSW 2000
Stock exchange listing	Next Science Limited shares are listed on the Australian Securities Exchange (ASX:NXS)
Website	www.nextscience.com
Corporate governance statement	www.nextscience.com/corp-governance/